Application:
Applies to the Society and its affiliates

History:
Approved by the Society Board of Directors on May 30, 2019
Amended and approved by the Society Executive Committee on December 19, 2019, July 23, 2020 and September 9, 2021.
TABLE OF CONTENTS

1. Background .................................................. 3
2. How Topics are Selected .............................. 3
3. Guidance Products ........................................ 4
4. Panel Composition .......................................... 4
5. Protocol ....................................................... 5
6. Systematic Literature Review ............................ 5
7. Unpublished Data from Meeting Proceedings (Abstracts) .............................. 6
8. Summarizing the Evidence ............................... 6
9. Formulating Recommendations ...................... 6
10. Certainty of Evidence and Strength of Recommendations .............................. 7
11. Additional Topics ........................................... 8
    a. Cost Considerations .................................. 8
    b. Health Disparities .................................... 8
    c. Patient-Clinician Communication ................ 8
    d. Biosimilars ............................................. 8
12. Open Comment .............................................. 9
13. Review Process ........................................... 9
14. Dissemination and Implementation: Clinical Tools and Resources .. 9
15. Guideline Update Process ............................ 10
17. Requests for Official Representatives ........... 15
18. Joint Guideline Development ....................... 16

Appendix I: Topic Prioritization: Topic Submission and Selection Guide .............................. 17
Appendix II: Topic Submissions: Priority Setting ........................................... 18
Appendix III: Provisional Clinical Opinions .................................................. 20
Appendix IV: Endorsement ...................................... 22
Appendix V: Adaptation ....................................... 25
Appendix VI: ASCO Endorsement/Adaptation Request Form .............................. 28
Appendix VII: ASCO Expert Reviewer Content Review Form ...................................... 29
Appendix VIII: Evidence Based Medicine Committee: Responsibilities and Authorities .................................................. 31
Appendix IX: Panel Composition: Expert Panel Responsibilities and Authorities .................................................. 35
Appendix X: Protocol Worksheet ........................... 39
Appendix XI: Consensus Methodology .................. 46
Appendix XII: GRADE Approach for Rating Certainty of Evidence and Strength of Recommendations .................................................. 51
Appendix XIII: Options for Collaboration: ASCO Representative Request Form .................................................. 53
Appendix XIV: Options for Collaboration: Joint Guidelines .................................................. 55

Appendix XV: Additional Sample Tables and Figures
    1. QUOROM Diagram ...................................... 57
    2. Cost ....................................................... 58

© American Society of Clinical Oncology 2021. All rights reserved.
1. BACKGROUND

The American Society of Clinical Oncology (ASCO) Guideline Program Methodology Manual is designed to transparently communicate the methods in which ASCO develops clinical practice guidelines, provisional clinical opinions, endorsements and adaptations. The ASCO Guideline Program falls under the auspices of the ASCO Evidence Based Medicine Committee (EBMC) which acts on behalf of the ASCO Board of Directors on matters of clinical guidance (See EBMC R&A document, which may be updated from time to time at the discretion of the Board). The EBMC oversees topic prioritization, development, the formation and progress of expert panels, and is the review and approval body of all guideline products.

All funding for the Guidelines Program is provided by ASCO and expert panels are populated according to ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines. ASCO follows guideline development procedures as outlined by the Council of Medical Specialty Societies (CMSS) and the Institute of Medicine (IOM).

2. HOW TOPICS ARE SELECTED

ASCO strives to offer a comprehensive portfolio of practice guidelines to meet the needs of its members and the clinical oncology community. The EBMC selects and approves topics for which ASCO will develop guideline products. ASCO Guideline Advisory Groups make recommendations to the EBMC on identifying and prioritizing topics for guideline development or update. As delegated by the EBMC, Guideline Advisory Groups review the progress and direction of ASCO clinical practice guidelines relating to a disease site or cancer topic. Currently, Advisory Groups have been assembled in each of the following areas to oversee the portfolio of ASCO guidelines in the applicable disease state: breast cancer, gastrointestinal cancer, genitourinary cancer, thoracic cancer, head and neck cancer, gynecologic cancer, supportive care, survivorship, resource stratification, and multi-site cancer topics.

ASCO Guideline Advisory Groups review and prioritize guideline topic proposals submitted through an online survey on an annual basis. Each spring, survey responses are solicited to provide individuals the opportunity to submit topics for guideline development. The survey asks questions such as:

- Is there uncertainty or controversy about the relative effectiveness of available clinical strategies for the condition(s) for which guideline is proposed?
- Is there perceived or documented variation in practice in the management of a given condition/use of health care intervention?

The Topic Submission and Selection Guide (Appendix I) may help in the assessment of the need for a guideline on a given topic. Factors considered when selecting and prioritizing topics include the burden or importance of the condition/intervention, the degree of uncertainty or controversy about the relative effectiveness of existing clinical options, and/or variation in practice in the management of the condition/intervention. In the fall, topics are submitted to the appropriate Guideline Advisory Group (AG) for review during their annual priority setting process (Appendix II). To submit a topic at any time throughout the year, please visit https://www.surveymonkey.com/s/ascoguidelinesurvey.
3. GUIDANCE PRODUCTS

In addition to the development of Clinical Practice Guidelines, ASCO also provides clinical guidance through other products such as:

- Provisional Clinical Opinions
- Guideline Endorsements
- Guideline Adaptations
- Resource-Stratified Guidelines

The Provisional Clinical Opinion (PCO) offers timely clinical direction 1) following the publication or presentation of potentially practice-changing data from major studies, 2) in areas of emerging evidence, or 3) as interim direction pending the development or updating of an ASCO clinical practice guideline. In contrast to practice guidelines, PCO’s are characterized by a different level of user obligation (clinical opinions versus recommendations), smaller expert panels, targeted systematic literature reviews, concise manuscripts, and expedited review and approval by the EBMC leadership (Past-Chair, Chair, Chair-Elect, and Board Liaison) if needed (Appendix III).

Endorsement (Appendix IV) or Adaptation (Appendix V) of guidelines developed by other organizations, is considered if the guidelines are judged to be of interest to the ASCO membership and align with the priorities of the EBMC. Endorsement by ASCO indicates that an independent ASCO Expert Panel agrees with all the recommendations as drafted by the developing organization, whereas for Adaptations, an ASCO Expert Panel adds qualifying statements or alters recommendations. ASCO uses a formal review process for endorsing and adapting clinical practice guidelines developed by other health professional organizations (Shah et al1). Organizations seeking Endorsement or Adaptation by ASCO may submit a request for endorsement or adaptation through the ASCO Guideline Endorsement/Adaptation Request form (Appendix VI) and guidelines are assessed by content experts using the ASCO Expert Reviewer Content Review Form (Appendix VII).

Resource-Stratified Guidelines provide expert guidance for settings in which maximal resources are not available to complement local guidelines. These guidelines use ASCO’s systematic review processes, formal consensus methodology, and modified ADAPTE methodology to developed stratified recommendations for the basic, limited, and enhanced settings (Al-Sukhun et al2).

4. PANEL COMPOSITION

Once a topic is approved for development by the EBMC, an Expert Panel is assembled. All ASCO systematic review-based guideline products are developed by a multidisciplinary Expert Panel supported by ASCO guidelines staff with health research methodology expertise. The Expert Co-Chairs and ASCO staff assemble a list of Expert Panel members which the EBMC leadership reviews and approves. Each Expert Panel should have a representative from the ASCO Practice Guidelines Implementation Network (PGIN) and at least one patient representative. Prospective members are sent an invitation to join the Expert Panel, along with the Expert Panel Responsibilities and Authorities (Appendix IX) document. In addition, slide sets have been developed for the

---


© American Society of Clinical Oncology 2021. All rights reserved.
roles of Co-Chair, Member, PGIN Representative, and Patient Representative to further explain the responsibilities and processes.

Guideline expert panels are assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines and the CMSS Code for Interactions with Companies. ASCO requires disclosure by individuals involved in drafting, reviewing, and approving guideline recommendations and sets limits on the financial relationships that panel members and reviewers can have with Companies that could reasonably be affected by care delivered in accordance with guideline recommendations. To carry out this policy, potential panel members must complete a conflict of interest disclosure form prior to formal invitation to serve on the panel. Following the COI policy, ASCO develops a list of “affected companies”. A Company is an “affected Company” if there is a reasonable likelihood of direct regulatory or commercial impact (positive or negative) on the entity as a result of care delivered in accordance with guideline recommendations. Decisions to invite Expert Panel members and evaluations of any actual or perceived conflict of interest are made at the full discretion of ASCO.

Once the Expert Panel is assembled, guideline development can begin. The work of a panel is confidential. The materials members receive, any discussions, and the decisions made by the panels are subject to ASCO’s policies on Confidentiality and may not be shared with anyone outside the ASCO leadership and staff. Some of the materials may be highly sensitive and there could be legal penalties for using or disclosing the information inappropriately. Non-authors, including but not limited to third parties are not permitted prepublication access to ASCO-approved clinical practice guidelines or related materials developed for ASCO publication and public dissemination. An exception is individuals solicited by ASCO for the purposes of invited and confidential peer review. In certain cases, ASCO will share draft guideline documents with outside parties. In these select cases, the parties are required to sign a Non-Disclosure Agreement.

5. PROTOCOL

The Protocol specifies the purpose of the guideline product, target patient population, clinical outcomes of interest, and their importance for decision-making, key features of the systematic literature review, and a proposed timeline for completion. ASCO staff, the Expert Panel Co-Chairs, and possibly other panel members selected by the Co-Chairs (the Expert Panel Steering Committee), will typically draft the protocol for full panel review. For consistency a Protocol Worksheet (Appendix IX) is used.

Once the Co-Chairs have approved a first draft of the Protocol, the Protocol will be shared with the full Expert Panel. At the discretion of the Guidelines Director, the EBMC leadership and/or the EBMC Methodology Subcommittee may review the Protocol to make suggestions for revision intended to clarify aspects of the plan for developing the guideline. These suggestions are sent to the Expert Panel Co-Chairs. Work on the systematic literature review can proceed upon the sign-off of the Protocol by the Expert Panel.

6. SYSTEMATIC LITERATURE REVIEW

Upon approval of the Protocol, a systematic review of the medical literature is conducted. ASCO staff use the information entered into the Protocol, including the clinical questions, inclusion/exclusion criteria for qualified studies, search terms/phrases, and range of study dates, to perform the systematic review. Literature searches of selected databases, including The Cochrane Library and Medline (via PubMed) are performed. Working with the Expert Panel, ASCO staff complete screening of the abstracts and full text articles to determine eligibility for inclusion in the systematic review of the evidence.
7. UNPUBLISHED DATA FROM MEETING PROCEEDINGS (ABSTRACTS)
Approved by the ASCO Board of Directors September 7, 2017

Unpublished data from meeting abstracts are not generally used as part of normal ASCO guideline development ("Meeting Data"). However, abstract data from reputable scientific meetings and congresses may be included on a case-by-case basis after review by the EBMC leadership. Expert Panels should present a rationale to support integration of abstract data into a guideline. The EBMC leadership will consider the following inclusion criteria for the unpublished scientific meeting data: 1) whether the data were independently peer reviewed in connection with a reputable scientific meeting or congress; 2) the potential clinical impact of the unpublished data; 3) the methodological quality and validity of the associated study; 3) the potential harms of not including the data; and 4) the availability of other published data to inform the guideline recommendations.

8. SUMMARIZING THE EVIDENCE
After the systematic review is completed, a GRADE evidence profile and summary of findings table is developed to provide the guideline panels with the information about the body of evidence, judgments about the quality of evidence, statistical results, and certainty of the evidence ratings for each pre-specified included outcome. Example templates of these summary tables are provided in Appendix XV.

9. FORMULATING RECOMMENDATIONS
After the systematic review of the literature is completed, Expert Panel members review the evidence profile and summary of findings and draft the guideline recommendations for clinical practice.

Evidence-Based Approach to Guideline Development

ASCO guideline recommendations are developed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology (https://gdt.gradepro.org/app/handbook/handbook.html) This method helps Guideline Expert Panels systematically develop evidence-based, clear, transparent, and implementable recommendations. The wording of recommendations is intentional to aid in understanding and interpretation for end users. The process of developing recommendations incorporates specifying the patients or population, detailing the intervention, and specifying the comparator, when appropriate. The words “must”, “should”, “may”, “may not”, “should not”, and “must not” are often used to describe the level of obligation for the recommendation and correspond with recommendation strength. In addition to strong or weak recommendations, there may be a recommendation to use interventions only in research. If there is insufficient evidence to support a decision for or against an intervention, further research could reduce the uncertainty about the effect of the intervention, and this research is thought to be of high value. Expert Panels may also choose not to make a recommendation for or against an intervention. Additionally, Expert Panels may choose to issue good practice statements. These statements represent the guideline panel's view of optimal practice, but are not graded. Panels should use good practice statements when high quality indirect evidence is available, but it would not be a good use of the panel's limited resources to conduct formal evidence summaries. These good

---

4 Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015 May; 68 (5) 597-600
practice statements should be used sparingly.\textsuperscript{5} This process for recommendation formulation helps the Expert Panel focus the discussion, avoid using unnecessary and/or ambiguous language, and clearly state its intentions.

**Consensus-Based Approach to Guideline Development**

Approved by the ASCO Board of Directors 2010

In clinically important areas where there is limited evidence or a lack of high-quality evidence to inform clinical guidance recommendations, ASCO uses a formal consensus methodology based on the modified Delphi technique (Appendix XI) (Loblaw et al.)\textsuperscript{6}.

**10. CERTAINTY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS**

The quality and usability of ASCO’s guidelines is enhanced by transparency about the quality and strength of evidence that informs guideline recommendations. ASCO adopted the GRADE Methodology as the recognized standard in guideline development methodology. The ASCO Evidence Based Medicine Committee voted to adopt the use of GRADE methodology for grading the certainty of evidence and strength of recommendations (http://www.gradeworkinggroup.org/). The GRADE Handbook details the approach for grading the quality of evidence and strength of recommendations, and its application to ASCO Guidelines is summarized below, additional details are available in Appendix XII.

- **Certainty of evidence.** The quality of evidence used to inform a given recommendation is assessed to evaluate its validity, reliability, and consistency. The quality of evidence is rated for each outcome across studies. Factors assessed when rating the quality of evidence include study design, consistency of results, directness of evidence, precision, publication bias, magnitude of effect, confounding, and dose-response gradient. This assessment considers the individual study quality ratings, the overall risk of bias, and the overall validity and reliability of the total body of evidence. The summary rating is an indication of the Expert Panel’s confidence that an estimate of the effect is adequate to support a particular recommendation. The certainty of the evidence is defined as one of four grades: high, moderate, low, or very low. Definitions are available in Table 1.

<table>
<thead>
<tr>
<th>Grade</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>High</td>
<td>We are very confident that the true effect lies close to that of the estimate of the effect.</td>
</tr>
<tr>
<td>Moderate</td>
<td>We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different</td>
</tr>
<tr>
<td>Low</td>
<td>Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect.</td>
</tr>
<tr>
<td>Very Low</td>
<td>We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect</td>
</tr>
</tbody>
</table>


Strength of recommendations. The Expert Panel provides a rating of the strength of each recommendation. This assessment reflects the extent to which a guideline panel is confident that desirable effects of an intervention outweigh undesirable effects, or vice versa, across the range of patients for whom the recommendation is intended. Recommendations may fall into two categories; strong and weak. Factors determining the strength of a recommendation include balance between benefits and harms, certainty of evidence, confidence in values & preferences, and resource use. Recommendations may be made for or against the use of an intervention.

11. ADDITIONAL TOPICS

Cost Considerations

Cost considerations and/or commentary about published cost-effectiveness analyses relative to the clinical question may be included in ASCO guidelines. When guidelines address questions where cost is a consideration (e.g. anti-emetics), then a table may be included that lists the drug acquisition costs of the available therapies (See Sample Cost Table).

Other examples of where a cost table may be considered are for comparisons of alternative diagnostic procedures where there are commonly available billing codes used for reimbursement. For complex multi-faceted procedures (i.e., sentinel lymph node biopsy, laparoscopic colectomy) there are many dimensions that must be evaluated, and a cost section should be considered carefully before inclusion in a guideline.

Cost-effectiveness of therapies can be a cancer policy issue, but such analyses are not the primary focus of ASCO clinical guidance. If economic analyses (cost-effectiveness, cost-utility, cost-benefit) are identified in the systematic literature review, then that evidence should be included as a distinct commentary in a cost section of the guideline. At present, no endorsement or rejection of the relative value of identified economic analyses are reflected in the recommendations generated by the expert panels.

Health Disparities

Disparities are addressed in the systematic review and specific studies should be referenced in the guidelines. Efforts are underway to expand this section of the guideline.

Patient-Clinician Communication

ASCO has incorporated a patient communication section into each guideline. This section presents possible options on how oncologists can communicate with their patients. In many cases, the patient representative assists in drafting this section.

Biosimilars

ASCO supports integration of FDA approved biosimilars into clinical practice guidelines for their approved indications. Some FDA-approved oncology biosimilars often exhibit narrower indications than the related, approved reference biologic. ASCO supports the use of oncology biosimilars that have received FDA approval, and supports the application of biosimilars in clinical practice according to the FDA-approved clinical indications, which may differ slightly from the reference biologic indication(s). The reflexive switch between a reference
product and the biosimilar without the knowledge of the prescriber is not recommended. Of note, none of the approved biosimilar products in the U.S thus far have met FDA criteria to be designated as interchangeable.

12. OPEN COMMENT
Approved by the ASCO Board of Directors September 7, 2017

ASCO Guidelines are available for open comment for a 2 to 3-week period. Guideline recommendations available for open comment are posted on asco.org/open-comment-guidelines. Prospective reviewers must contact ASCO to request to review the draft guideline recommendations and are required to sign a non-disclosure and confidentiality agreement before receiving the draft guideline recommendations. Reviewers must identify themselves by name and affiliation; anonymous comments will not be accepted. Guidelines staff review and summarize comments and bring relevant comments to the Expert Panel Co-chairs, and to the entire panel if necessary. Any changes made from the open comment process will be reviewed by the entire panel prior to EBMC approval. Comments are advisory only and ASCO is not bound to make any changes based on feedback from open comment. ASCO does not respond to reviewers or post responses to comments; however, major edits to the draft will be reflected in the open comment discussion.

13. REVIEW PROCESS

ASCO has a rigorous review process for guidelines. After the draft has been approved by the Expert Panel, the guideline is independently reviewed and approved by the EBMC. Select members of the EBMC are asked to critically review the guideline prior to the next scheduled EBMC meeting. The EBMC members then present the results of their reviews to the full committee, discuss the review with the full committee, and the EBMC votes on whether to approve the guideline (with recusals from members who have relationships with affected companies). Approved ASCO Guidelines are then submitted to the JCO for consideration of publication. Submitted guidelines are subject to an embargo policy and cannot be posted publicly prior to publication.

14. DISSEMINATION AND IMPLEMENTATION: CLINICAL TOOLS AND RESOURCES

ASCO produces Clinical Tools and Resources to more widely disseminate, in a practical and user-friendly form, the recommendations contained in the guidelines. These CT&Rs include:

1. **Patient Material**: Each guideline is accompanied by a short summary containing information such as: key messages, questions to ask your doctor, and what this means for patients. The patient guides are developed by ASCO's Communication Department and are available on cancer.net.

2. **Power Point Slide Set**: Slides containing sections like Clinical Questions, Background, Methodology, Evidence, Recommendations, and Implications. These slides are designed to be used during Tumor Boards, Grand Rounds, and similar lectures. A slide set is developed for every guideline. An example is the [Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer Slide Set](#).

3. **Flow Sheet or Algorithm**: These tools could be used by clinical practices in their daily activities and included in patients’ records. The intent is to create a practical product that will facilitate guideline adherence in day-to-day situations for the practicing clinician. An example is the [Management of Salivary Gland Malignancy Algorithm](#).

4. **Tables**: If applicable, ASCO will develop tables with the recommendations and other information like dosing, for example: [Antiemetics Drug, Dose, and Schedule Table](#).
5. **Decision Aid/Discussion Guide:** The Decision Aids discuss benefits and risks of interventions from the Guidelines and include opportunities for patients to weigh their options. ASCO's [Medications to Reduce the Risk of Developing Breast Cancer Decision Aid Tool](#) is an example.

6. **Guidelines App:** ASCO’s guidelines are disseminated through the ASCO Guidelines App (available for download on [iOS](#) and [Android](#)).

7. **Podcasts** ASCO Guidelines Podcast Series (available on [Apple Podcasts](#), [Google Podcasts](#), or on the [Podcast Page](#)). Each guideline product is accompanied by a podcast interview with a panel member(s) highlighting key recommendations from the publication.

8. **Webinars**

9. **Guideline Pocket Cards**

### 15. GUIDELINE UPDATE PROCESS

ASCO is committed to the currency and validity of its guidelines, an annual assessment, review, and approval strategy has been established. ASCO adapted a signals approach\(^8\) to ensure a consistent approach to the updating of guidelines. The goals of this effort are a) to keep guideline products up to date within 3 years of publication (or time of last update), b) have readers aware of the status of the guidelines, and c) to be responsive to new and emerging evidence that can alter guideline recommendations. This can be done by:

1. Guideline Co-Chairs conducting annual assessments of updating need
2. Guidelines Advisory Groups conducting regular assessments and prioritization of updating need
3. Having an expedited response for important recommendation-altering evidence
4. Communicating the status of guideline products on the ASCO Website
5. Archiving guidelines that are no longer of relevance

**Guideline Assessment by Co-Chairs**

ASCO staff request that guideline Co-Chairs assess the currency of their guidelines on an annual basis, or sooner as circumstances warrant, based on their content expertise and any supporting evidence provided by ASCO Staff. The assessment includes the need for an update as well as the type of update. For example:

Do you think that the guideline should be updated at this time (either because of the availability of new evidence that may alter the recommendations or based on the date of publication with the goal of keeping all of the ASCO guidelines up to date)?

- **Yes:** an update is needed at this time
- **No:** an update not needed at this time
- **Unsure:** if an update is needed at this time

If an update were to be considered at this time, please assess how you would prioritize an update

- **High:** New evidence has been published; one or more recommendations require substantive revision, new recommendations may be needed, or recommendations may be invalidated

---

• **Medium:** New evidence has been published; recommendations require revision or new recommendations may be needed, but not imminently
• **Low:** New evidence may have been published, but the recommendations are still valid
• **Very low:** No new evidence has been published and/or the recommendations are still valid. An update would only be conducted to keep the guideline current to within 3 years of publication.

If an update were to be considered at this time, what type of update ASCO should consider:

• **Full:** The full guideline requires review and many of the recommendations will need updating
• **Partial:** Portions of the guideline requires review and one or more recommendations will need updating
• **Minor:** Very little of the guideline requires review and while minor edits or clarifications may be needed, the recommendations do not need updating. The guideline may need to be updated to confirm the recommendations are valid to the present day.
• **Expedited:** Important new evidence has emerged that will alter one or more recommendations
• **Archive:** The guideline is deemed no longer relevant and should not be used to guide practice

**Guideline Assessment and Prioritization by Guidelines Advisory Groups**

Once the individual guideline assessment by the Co-Chairs is completed, the Guidelines Advisory Groups assess the updating status of the guidelines on an annual basis and prioritize non-urgent updates. The updating priority list is reviewed and approved by the EBMC at the annual fall meeting. Urgent update priorities are reviewed and approved by the EBMC leadership as they arise throughout the year.

**Expedited Review**

Once a high-priority and urgent update is identified and approved for development by the EBMC leadership, a plan for expedited review should be established. ASCO staff can work with the Expert Panel Co-Chairs and EBMC leadership to establish the development, approval and publication strategy for each expedited review. The plan could include:

• A smaller update panel to adhere to expedited timelines established by the Expert Panel Co-Chairs
• A targeted data review and extraction process to focus on recommendation-changing data
• The EBMC agrees to expedite review and approval (including leadership review and approval)
• JCO publication and JOP summary using a minimal component template.
  o The full set of recommendations are provided within the expedited review

In rare cases, bypass publication and post directly to ASCO Website. The threshold for embarking on ASCO guideline updates that translate into new or revised recommendations include:

• a potentially invalidating change in evidence: opposing findings, evidence of substantial harm, evidence of a superior new treatment; and
• A major change in evidence: important changes in efficacy but not opposing findings, expansion of treatment such as evidence of efficacy in a new population, important caveat.

Of note, there can be reasons other than the scientific literature to initiate a guideline update, including regulatory decisions that affect existing practice recommendations and can require rapid, ad hoc updates.
Response to Requests for Revising Guidelines or Adding New Material

Individuals may submit comments or new evidence at any time regarding existing guidelines via the online form. All submitted evidence is reviewed by ASCO guidelines staff, the Expert Panel Co-Chairs, and the entire panel, if needed. All submissions are considered carefully and evidence that may alter one or more recommendations may be used to prompt an update. ASCO is not able to respond to those who submit information or convey any information around decisions made regarding the evidence submission.

Guideline Status

ASCO notes the current guideline status on the respective page on asco.org as Current, Affirmed, Review in Progress, or Archived. Please find a brief description of these terms below:

- **Current:** The guideline was published within the last 3 years. The recommendations are current, accurate, and valid
- **Affirmed:** The guideline was published more than 3 years ago, and the recommendations are current, accurate, and valid
- **Review in Progress:** The guideline is being assessed for currency or an update is in progress. The status of the guideline and recommended care options may change as a result
- **Archived:** The guideline recommended care options are no longer current or valid. This guideline should be used for historical purposes only.

16. RAPID RECOMMENDATION UPDATE PROCESS

Background and Overview

ASCO Rapid Recommendation Updates, which can be characterized as rapid oncology analysis and recommendations (ROAR) guideline update products, are special articles that highlight updates to select ASCO guideline recommendations. These rapid updates act as a response to the identification of high-quality practice-changing data. The goal of these updates is to disseminate the identified evidence and updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.

**ASCO Rapid Recommendation Update: Assessment Criteria**

ASCO strives to offer a comprehensive portfolio of practice guidelines in a fast-paced research environment. The decision to develop a rapid recommendation update is determined by several factors, including the strength and quality of evidence, an unbiased assessment of the evidence on the clinical impact on practice, and the need to communicate recommendation-changing evidence to the practicing community as soon as possible. The identification of new evidence that may prompt a rapid recommendation update should be made through the ASCO submission form https://www.surveymonkey.com/r/guidelineevidence or via email to guidelines@asco.org, through the same process as submissions for standard guideline updates.

The criteria for a rapid recommendation update are:

1. that the identified evidence is of high methodological quality,
2. there is high certainty among experts that results are clinically meaningful to practice,
3. the identified evidence represents a significant shift in clinical practice from a recommendation in an existing ASCO guideline (e.g., change from recommending against the use of a particular therapy to recommending the use of that therapy; or a reversal to a recommendation) such that it should not wait for a scheduled guideline update.
An example of evidence meeting these criteria would be a large phase III trial, conducted and powered appropriately, that detected important differences between patient groups in primary outcomes, such as disease-free or overall survival, that are both clinically and statistically significant.

**ASCO Rapid Recommendation Update: Staff Evidence Assessment and Disclosures Review**

When ASCO staff become aware of high-quality practice-changing evidence that may alter existing ASCO guideline recommendations, they will conduct a critical review of the strength and quality of the identified evidence using the GRADE methodology.

Concurrently, ASCO staff review the Affected Companies list of the guideline and update the list to include any additional affected companies associated with the newly identified evidence. The immediate past co-chairs and expert panel members are asked to update their disclosures to confirm that disclosure information is correct and current to be considered eligible for a rapid recommendation update panel. The disclosures of the immediate past guideline co-chairs and members of the expert panel are checked against the updated Affected Companies list.

**ASCO Rapid Recommendation Update: Evidence Assessment by Content Experts and EBMC Approval**

The co-chairs of the immediate past guideline review the identified evidence along with the staff’s evidence assessment and provide an opinion on whether the evidence meets the criteria for a rapid recommendation update. Members of the immediate past guideline expert panel, or other content experts if needed, may also be asked to provide input about whether the new evidence meets the rapid recommendation update criteria.

The Evidence Based Medicine Committee (EBMC) leadership (Chair, Immediate Past-Chair, Chair-Elect, and Board Liaison) are asked to review and approve the development of a rapid recommendation update considering the expert panel’s recommendation and their own assessment. If the update is not approved for development by the EBMC leadership, the evidence will be included in the next scheduled update.

**ASCO Rapid Recommendation Update: Expert Panel Selection**

Once a rapid recommendation update is approved by the EBMC decision group, a rapid update expert panel is assembled. All ASCO rapid recommendation updates are developed by a multidisciplinary expert panel and are supported by an ASCO guidelines staff member with health research methodology expertise. The expert panel co-chairs and ASCO staff assemble a panel of content experts with a minimum of 5 members. Immediate past guideline co-chairs and guideline panel members will be re-assembled to the extent possible for greater expediency.

The membership of the expert panel is chosen in accordance with the panel composition requirements of ASCO’s [Conflict of Interest Policy Implementation for Clinical Practice Guidelines](https://www.asco.org). The EBMC leadership reviews and approves the expert panel roster for the rapid recommendation update.

**ASCO Rapid Recommendation Update: Literature Review and Recommendation Development**

A systematic literature review focused on the updated recommendation will be conducted by ASCO staff. Specifically, the immediate past guideline literature search strategy will be updated and filtered by search criteria specific to evidence informing the recommendation under review. All identified evidence will be quality-appraised using the GRADE methodology as outlined in Section 10 of this ASCO Guideline Methods Manual.
procedures used to draft the rapid recommendation update and deliberations by the expert panel will follow
routine methods for all guidance products as outlined in this ASCO Guideline Methods Manual.

The expert panel review and approval of the rapid recommendation update will follow the methods outlined in
this ASCO Guideline Methods Manual and will be reported briefly in a methods section of the published update.

**ASCO Rapid Recommendation Update: Review and Approval Procedures**

Upon expert panel majority approval, regular EBMC review and approval procedures and timelines will apply,
except in instances where greater expediency is required to better disseminate practice changing
recommendations. Although the EBMC meets on a regular basis throughout the year, if expedited review and
approval are needed, an ad hoc meeting will be scheduled or an email vote will be held, subject to typical recusal
requirements of the ASCO Conflict of Interest Policy for Clinical Practice Guidelines.

**ASCO Rapid Recommendation Update: Dissemination Strategy**

Upon EBMC approval, ASCO Daily News and Communications staff will be notified, and a communication strategy
will be developed in line with other ASCO guidance products. The strategy may include a daily news article, press
release, media blast, or social media release. In addition, the ASCO website will be immediately updated, and any
associated guideline tools and materials will be revised to reflect the recommendation change. As part of the
dissemination strategy prior to publication, advance notice through the website and any other communication
vehicle will only contain information on the recommendation change itself. Greater details and rationale will be
provided in the published material. The disclaimer below will be used or referenced in all communications.

**ASCO Rapid Recommendation Update Manuscript Format**

The rapid recommendation update will be formatted for publication submission with a format intended to be
brief, but also include an introduction, methods, evidence review summary, recommendation, and conclusion
section along with a legal disclaimer section akin to the standard section in ASCO practice guidelines.

**ASCO Rapid Recommendation Update Submission for Publication**

The recommendation update will be submitted to a peer reviewed ASCO journal for publication consideration
and editorial review as a special article “ASCO Rapid Recommendations” reflecting journal formatting and the
ASCO brand.

If non-recommendation-altering revisions are required through the peer-review process, the expert panel will
revise the draft accordingly and respond to reviewers. If revisions to the recommendation are required, the panel
will revise the draft accordingly and the draft will once again be submitted to the EBMC for review and approval.
After EBMC approval, the website and any other materials will be revised to reflect the revised recommendation
and the manuscript will be resubmitted to the Journal.

**ASCO Rapid Recommendation Update: ASCO Journal Process**

1. Once published online, the rapid recommendation update is linked to the original guideline, and vice
   versa. A banner may be added to the original guideline alerting readers that an update is available. The
   update will also be posted on the ASCO site; however, any press releases should point readers to the JCO
   publication.
2. Generally, rapid recommendation updates have no more than 5 authors.

3. Text of the recommendation update: limit of 750 words, including references

4. A single guideline may have a maximum of two rapid updates; beyond that, the full guideline should be updated and submitted to JCO as a new submission.

Guideline Disclaimer
The Clinical Practice Guidelines and Rapid Updates published herein are provided by the American Society of Clinical Oncology, Inc. (ASCO) to assist providers in clinical decision making. The information herein should not be relied upon as being complete or accurate, nor should it be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. With the rapid development of scientific knowledge, new evidence may emerge between the time information is developed and when it is published or read. The information is not continually updated and may not reflect the most recent evidence. The information addresses only the topics specifically identified therein and is not applicable to other interventions, diseases, or stages of diseases. This information does not mandate any particular course of medical care. Further, the information is not intended to substitute for the independent professional judgment of the treating provider, as the information does not account for individual variation among patients. Recommendations specify the level of confidence that the recommendation reflects the net effect of a given course of action. The use of words like “must,” “must not,” “should,” and “should not” indicates that a course of action is recommended or not recommended for either most or many patients, but there is latitude for the treating physician to select other courses of action in individual cases. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ASCO does not endorse third party drugs, devices, services, or therapies used to diagnose, treat, monitor, manage, or alleviate health conditions. Any use of a brand or trade name is for identification purposes only. ASCO provides this information on an “as is” basis and makes no warranty, express or implied, regarding the information. ASCO specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information, or for any errors or omissions.

Guideline and Conflicts of Interest Statement
The Expert Panel was assembled in accordance with ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines (“Policy,” found at http://www.asco.org/guideline-methodology). All members of the Expert Panel completed ASCO’s disclosure form, which requires disclosure of financial and other interests, including relationships with commercial entities that are reasonably likely to experience direct regulatory or commercial impact as a result of promulgation of the guideline. Categories for disclosure include employment; leadership; stock or other ownership; honoraria, consulting or advisory role; speaker’s bureau; research funding; patents, royalties, other intellectual property; expert testimony; travel, accommodations, expenses; and other relationships. In accordance with the Policy, the majority of the members of the Expert Panel did not disclose any relationships constituting a conflict under the Policy.

17. REQUESTS FOR OFFICIAL REPRESENTATIVES

ASCO receives requests from other organizations to appoint Official ASCO Representatives to participate in guideline development panels or other related activities. While serving on guideline development bodies outside of ASCO, the representatives can bring the clinical oncology perspective to the developing guideline. The representative can inform ASCO staff and the EBMC Leadership on the guideline development progress.
To request Official ASCO Representatives, guideline developing organizations must complete the ASCO Representative Form (Appendix XIII) and submit it to guidelines@asco.org. If the initiative is in alignment with ASCO’s guideline development strategy or the overall goals of ASCO, the EBMC Leadership will approve and appoint the member.

Conversely, organizations may also be asked to nominate representatives to serve on an ASCO guideline Expert Panel on behalf of their organization.

Requesting or receiving a representative for a guideline panel IS NOT an endorsement of the guideline or of the requesting organization by ASCO. ASCO does not review or approve guidelines as a result of nominating representatives unless a separate endorsement or joint development agreement is in place.

18. JOINT GUIDELINE DEVELOPMENT

ASCO and other organizations may also opt to jointly develop a guideline (Appendix XIV). The Expert Panel membership may be split, as appropriate for the subject matter, between ASCO representatives and representatives from the partnering organization. Depending on the type of joint initiative, the costs of development are shared according by the respective organizations. Organizations participating in joint guideline development sign a legal agreement to memorialize decisions about costs, copyright ownership, panel membership, publication processes, conflict of interest management, and other matters. The organizations also must agree on a conflict of interest policy to follow. Typically, the most stringent policy is followed. ASCO’s policy can be found at: https://asco.org/rwc. Requests for joint guideline development can be sent to guidelines@asco.org.
**APPENDIX I: TOPIC PRIORITIZATION: TOPIC SUBMISSION AND SELECTION GUIDE**

<table>
<thead>
<tr>
<th>G</th>
<th>Guidelines</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are there existing systematic-review based guidelines on the proposed topic? If yes, consider what extra value an ASCO guideline would add to the existing guidelines.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>U</th>
<th>Uncertainty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is there uncertainty or controversy about the relative effectiveness of the available clinical strategies for the condition(s) for which guideline is proposed? Consider providing examples or an assessment of this uncertainty.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>I</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>If a guideline were to be developed, assuming appropriate dissemination, consider whether it would make a significant impact on clinical decision-making/clinical outcomes and/or reduce practice variation.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>Differences</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are there perceived or documented differences in practice in the management of a given condition or health care intervention? Consider providing an assessment or references related to variations in practice patterns and whether disparities in access or delivery of care is based on factors such as: race/ethnicity, age, geographic location, gender, cost, etc.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is there scientific evidence of good quality to allow development of an evidence-based guideline? Please provide references if available and note that the absence of evidence does not disqualify topics for consideration (See ASCO’s Consensus Methodology).</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>D</th>
<th>Disease Burden</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is the disease burden/importance of the health care intervention large enough to warrant guideline development? Consider providing an estimate of the burden (e.g. incidence, prevalence, costs).</td>
<td></td>
</tr>
</tbody>
</table>

Please provide as much detail as possible. If the proposed topic does not fit these criteria, consider how an ASCO guideline would still be of significant utility to ASCO members.
Guideline Advisory Groups (AGs) review priorities after the ASCO Annual Meeting on a yearly basis. This coincides with the rotation of the Guideline AGs’ membership. The process is annotated below.

1. Topic submission is open access year-round through the ASCO website. Every spring a communications outreach invites the ASCO membership to submit topics for guideline development. In addition, various Committees, including the Quality of Care Council (QCC), the Clinical Practice Committee (CPC), and the Cancer Research Committee (CRC) are invited to submit topics.

2. Staff will survey the AG members for new topics.

3. Staff will contact colleagues from other guideline development organizations (e.g. Ontario Health (Cancer Care Ontario), American Urologic Association, College of American Pathologists, American Society of Radiation Oncology, etc.) on the status of related guidelines in progress or recently completed.

4. If applicable, staff will contact the Measures Steering Group liaison for information on the corresponding measures panel’s priorities.

5. Simultaneously, staff survey Guideline Panel Co-Chairs on the validity of recommendations of published guidelines/endorsements/adaptations/Provisional Clinical Opinions (Updating Assessment Form).
   a. ASCO staff review a list of guidelines for which they are responsible for assessing updating status (not necessarily conducting the update). Typically, this will be the last person to work on the effort or the person assigned to a specific AG.
      i. Assessment of the recommendations by Co-Chairs should occur after the one-year anniversary of the publication date of the guideline product.
      ii. Assessment of the literature search results should be provided to the Co-Chairs after the 3-year anniversary of the publication date of the guideline product. At this time, consideration of updating should be placed higher in the priority queue.
   b. Staff who are assigned the assessment of a guideline will contact the guideline Co-Chairs and ask them to assess the status of the recommendations as follows:
      i. Recommendations still valid no changes needed (candidate for non-substantive update).
      ii. Some recommendations in need of updating (candidate for rapid update).
      iii. A moderate number of recommendations in need of updating (candidate for focused update).
      iv. Full update required (candidate for substantive update).
   c. The Co-Chairs are also asked their opinion on the importance of an update at that time: High, Medium, or Low.
   d. Staff assigned to AGs will compile all updating assessments for AG review and prioritization for updating during the annual review process.
Sample Updating Assessment Form

<table>
<thead>
<tr>
<th>Topic</th>
<th>Date of Publication</th>
<th>Assessment Assigned to:</th>
<th>Guideline AG</th>
<th>Type of Product</th>
<th>Type of Update Recommended</th>
<th>Priority</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Non-substantive</td>
<td>Rapid</td>
</tr>
</tbody>
</table>

6. Staff will provide AG members with the current list of priorities; the list of guidelines in need of updates; results of the topic submission, including the rationale for the topic and any additional context provided by survey respondents; and endorsement requests.

7. AGs meet by teleconference to discuss all potential topics. Topics can be eliminated or deferred by the AG members.

8. Staff ask the AG members to independently rank the remaining topics. Results of the ranking exercise are provided to the AG members. A conference call may be scheduled to discuss the results, if needed.

9. The priority list of new guideline topics, updates, and endorsements is provided to the EBMC at its fall meeting for review and approval. An AG member/EBMC liaison present the results of the ranking exercise and the rationale for the topics selected to the EBMC.
APPENDIX III: PROVISIONAL CLINICAL OPINIONS

Provisional Clinical Opinion Procedures

Background and Overview
The Provisional Clinical Opinion (PCO) is intended to offer timely clinical direction to the ASCO membership 1) following the publication or presentation of potentially practice-changing data from major studies, 2) in areas of emerging evidence, or 3) as interim direction to the membership pending the development or updating of an ASCO clinical practice guideline. In contrast to practice guidelines, PCO’s do not make formal recommendations, are compiled by smaller expert panels, targeted systematic literature reviews, concise manuscripts, and if needed, expedited review and approval by the EBMC leadership and any invited content experts or ASCO Leadership/Board members.

Provisional Clinical Opinion Topic Selection
Topic selection will generally follow the ASCO guideline topic prioritization strategy; however, in cases of new or emerging topics where an expedited approach is needed, the EBMC leadership (Chair, Immediate Past-Chair, Chair-Elect, EBMC Board liaison) is responsible for accepting, reviewing and approving proposed PCO topics. PCO topic selection may be guided by the Topic Submission and Selection Guide that is used by the EBMC to guide the selection of topics for ASCO clinical practice guidelines. The guide prompts users to consider the burden or importance of the condition or intervention, the degree of uncertainty or controversy about the relative effectiveness of existing clinical options, the perceived or documented variation in practice management of the condition or the use of the intervention, the availability of evidence to inform practice recommendations, and the existence of other high-quality guidelines on the topic (Appendix I).

Evidentiary Basis for the PCO
Provisional clinical opinions are informed by a targeted systematic review of the literature. Only evidence that can inform the PCO is searched for as part of the systematic review; however, it is recognized that evidence is often lacking or emerging for these products and often expert consensus opinion is needed to inform the PCO.

Provisional Clinical Opinion Expert Panel
Once a PCO topic is approved by the EBMC, or EBMC leadership, an Expert Panel is assembled. All ASCO PCOs are developed by a multidisciplinary Expert Panel and are supported by ASCO guidelines staff with health research methodology expertise. The Expert Panel Co-Chairs and ASCO staff assemble a panel of content experts with approximately 10 or fewer members. Each Expert Panel should have a community oncologist representative from the Practice Guidelines Implementation Network (PGIN) and at least one patient representative. The membership of the expert panel is chosen in accordance with the panel composition requirements of ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines. The COI Procedures call for the majority of panel members to have no relationships with companies potentially affected by the PCO, and generally require panel Chairs and Co-Chairs to be free from relationships with affected companies.

Provisional Clinical Opinion Manuscript Format
The PCO document will include a general introduction that will; define the concept of a provisional clinical opinion, and provide an overview of the issue at hand; include a brief methodological section and a legal
disclaimer section akin to the standard section in ASCO practice guidelines; provide a summary of the evidence and the expert panel's deliberations; and, finally, it will summarize the provisional clinical opinions.

Review and Approval of the PCO
ASCO has a rigorous review process for PCO’s. After the draft has been approved by the Expert Panel, the PCO is reviewed and approved independently by the EBMC. Although the EBMC meets on a regular basis throughout the year, if expedited review and approval is needed, the PCO may be approved by the EBMC leadership (Past-Chair, Chair, Chair-Elect, and Board Liaison) and if needed, any invited content experts or select ASCO Leadership or Board members.

Publication of the PCO
PCOs are submitted for consideration of publication in one or more of ASCO’s journals and are posted online at asco.org. The PCOs are formatted to reflect journal formatting and the ASCO brand. Derivative products such as slide sets, recommendations table, and patient materials may be developed, and re-prints are available for PCOs.
APPENDIX IV: ENDORSEMENT

Endorsement Procedures

Overview
ASCO endorses clinical practice guidelines developed by other organizations to recognize the high-quality work of other guideline-developing organizations, avoid duplication of effort, and promote harmonized recommendations across guideline development groups.

The ASCO EBMC evaluates endorsement opportunities to determine whether the guideline addresses a gap in ASCO’s guideline portfolio and is a topic of interest to the ASCO membership. If the guideline meets these criteria, an Expert Panel is convened to formally assess the content, level of agreement with the evidence, and resulting recommendations presented within the guideline. An endorsement manuscript is prepared by the Expert Panel for EBMC review and approval.

ASCO Endorsements are submitted for consideration of publication in one or more of its journals, and recommendations are formatted to reflect journal formatting and the ASCO brand. Derivative products such as slide sets, recommendations table, and patient materials may be developed, and re-prints are available for endorsement materials.

ASCO’s updating procedures apply for endorsements (see ASCO’s Updating Policy and Procedures).

Endorsement Procedures

Organizations may submit guidelines for endorsement consideration by submitting the following to guidelines@asco.org:

1. Endorsement/adaptation Request Form
2. Copy of the guideline (published or unpublished)
3. Conflict of Interest Policy/procedures followed during development
4. Additional supporting documents as appropriate

At the time of submission, organizations are asked to indicate whether an Endorsement only approach is preferred, which indicates that no changes to the recommendations are requested, but other edits such as discussion points are considered part of the process. Alternatively, organizations may elect to pursue an Endorsement or Adaptation option, in which changes to the recommendation(s) are acceptable, if needed. It is possible that ASCO may reject the guideline for endorsement or adaptation.

Under the Endorsement option:

- Applicant organizations indicate they prefer no changes are made to the recommendations.
- ASCO edits such as clarifications, qualifying statements, or discussion points are considered an acceptable part of the process and can be included as part of the discussion.
- Guidelines undergo a more thorough triage process. It is understood that fewer endorsement
only requests will be selected for ASCO endorsement since there needs to be unanimous strong agreement with the recommendations among the initial content expert reviewers asked to assess the guideline (Appendix II. ASCO Expert Reviewer Content Review Form).

- An update of the literature search will not be performed for endorsement only requests. This means that the existing literature search of the candidate guideline must be current to within 1 year since the time of publication.
- Endorsements should be completed within an approximate 3-6 month timeframe.

Under the Endorsement or Adaptation option:

- Although initial submissions begin as an endorsement request, applicant organizations can indicate that revisions to recommendations are acceptable if deemed necessary by the ASCO Expert Panel, if so, an adaptation approach can be utilized. In addition to the conditions listed above for endorsements, edits could include the introduction of new evidence, revisions to existing recommendations, or additional recommendations offered by ASCO to further inform the ASCO membership.
- It is understood that a unanimous, strong agreement with the recommendations is not necessary among the initial content expert reviewers (ASCO Expert Reviewer Content Review Form).
- An update of the literature search will be performed.
- There is no set time frame for completion of guideline endorsement or adaptation development.

Upon submission to ASCO, candidate guidelines are assessed for methodological rigor by ASCO Staff. Guidelines meeting methodological criteria are assessed for content, scope and applicability by the leadership of an ASCO Guideline Advisory Group (AG) and later by the full AG during topic prioritization. In addition, a gap analysis is performed to determine the overall need for a guideline topic in the context of other guidelines at ASCO. Topics that are considered relevant to the mission of ASCO will be prioritized by the Guideline AG along with new guideline topics and guidelines in need of an update. The list of prioritized products is then further reviewed, prioritized and ultimately approved by the EBMC.

Guidelines considered for endorsement should be based on a systematic review. If the quality of the evidence identified through the systematic review is insufficient to inform recommendations, a consensus methodology may be utilized. There should be an explicit link between the evidence and the recommendations. Preferably, each recommendation will reflect the strength of the evidence and the strength of the recommendation. If consensus is used, a consensus methodology that limits the potential for bias (e.g. modified Delphi approach) is preferred. The guideline should report the conflict of interest procedures and the majority of expert panelists should be considered free from conflicts of interest. There should be no industry involvement of any nature supporting the development of the guideline.

Once a guideline is approved to be considered for endorsement (or adaptation), the original authoring organization and/or the copyright holder(s) is/are contacted for consent to proceed, and an ASCO expert panel is formed. If endorsement is not approved by the EBMC, the original authoring organization is informed of ASCO’s decision and the supporting rationale.

An ASCO Expert Panel of approximately 10 volunteer members is formed to review a guideline to be considered for endorsement. The expert content reviewers are typically invited and at least one of the original guideline authors is invited to serve on the Expert Panel. Multidisciplinary content experts, patient representatives, community oncologists, and other topic-relevant health providers comprise the remainder of expert panel.
As part of the organizational review and approval process, ASCO endorsements are reviewed independently of the expert panel by select members of the EBMC. The EBMC members present the results of the review to the full committee and the EBMC votes on whether to approve the guideline for endorsement. In cases where the expert panel and/or the EBMC cannot reach agreement on endorsement, ASCO may opt to discontinue development.

ASCO endorsements are submitted to the original authoring organization and copyright holder for review and permission to reprint any copyright material. Guideline endorsements are then submitted for consideration of publication to the *Journal of Clinical Oncology* (JCO). Although editorial revisions may be made through the publication process, the endorsement format is written according to a specific journal template. Typically, the JCO publication contains the following information: title and the group responsible for development of the original guideline, purpose and rationale, methods used, target population, endorsed recommendations and commentary summarizing the ASCO perspective including any additions or modifications specific to the ASCO membership.

A summary of the endorsement is also submitted to the *Journal of Oncology Practice* (JOP) for consideration of publication. The summary consists mainly of the recommendations and any relevant discussion points. Derivative products such as slide sets, recommendations tables, and patient materials may be developed, and reprints are available for adaptation materials.

Updating procedures for all ASCO guideline products follow an established updating process (see ASCO’s Updating Process and Procedures). If the need for an update is identified, ASCO staff will reach out to the originating guideline organization to assess their interest in updating the original guideline. If a guideline update is planned, ASCO may opt to wait for the guideline update or may release a provisional update until the guideline update is completed. If there are no plans to update the guideline, ASCO will undergo an update and release it as an adaptation. ASCO will share the update evidence and recommendations with the originating guideline organization.
APPENDIX V: ADAPTATION

Adaptation

Overview
ASCO engages in the adaptation of clinical practice guidelines to recognize the high-quality work of other guideline-developing organizations, avoid duplication of effort, and promote harmonized recommendations across guideline development groups.

ASCO adaptations are informed by the ADAPTE methodology (the ADAPTE process: Resource toolkit for guideline adaptation, version 2.0.; http://www.g-i-n.net). The objective of the ADAPTE process is to take advantage of existing guidelines in order to enhance efficient production, reduce duplication, and promote the local uptake of quality guideline recommendations. Adaptation occurs either as part of ASCO de novo guideline development or upon formal submission by another organization.

A guideline submitted by another organization must be determined by the EBMC to address a current gap in ASCO’s guideline portfolio and address a topic of interest to inform the ASCO membership. Upon approval, a multidisciplinary expert panel is convened to formally assess the content, level of agreement with the evidence, and resulting recommendations presented within the guideline. The expert panel then drafts an adaptation manuscript for the EBMC to review and approve.

ASCO adaptations are submitted for consideration of publication in one or more of its journals, and recommendations are formatted to reflect journal formatting and the ASCO brand. Derivative products such as slide sets, recommendations table, and patient materials may be developed, and re-prints are available for adaptation materials.

Established updating procedures apply for ASCO adaptations (see ASCO’s Updating Process and Procedures).

Adaptation Procedures

Adaptation as part of ASCO De Novo Guideline Development

Topic Development and Systematic review
As part of de novo guideline development, choice of topic, question, study selection criteria and literature search are conducted; starting with the protocol. If existing guidelines are identified in the course of the systematic review, then adaptation of one or more guidelines is considered.

- The guideline(s) are submitted to expert content reviewers to assess applicability
- The decision to adapt a specific guideline or guidelines, is based on:
  - The results of the content review and the level of agreement with the recommendations
  - A quality appraisal of available guideline(s) (see below)
  - The time since completion of the best available guideline(s)
- After selecting guideline(s) to adapt, a search for relevant new evidence (RCTs, systematic reviews, &/or meta-analyses) that might modify recommendation(s) is conducted after the closing date of the guidelines’ literature
searches (if available) or their publication dates.

Quality Appraisal of Clinical Practice Guidelines and Systematic Reviews

- The Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument is used to appraise clinical practice guidelines. Guideline(s) to adapt would be selected in descending order of preference, as follows:
  - systematic review-based
  - formal consensus-based
  - informal consensus (opinion)-based
- The Assessment of Multiple Systematic Reviews (AMSTAR) measurement tool is used to appraise the methodological quality of systematic reviews

Synthesizing the Evidence

Recommendations and the level of supporting evidence are extracted into a matrix.

- New recommendations are accepted by the Panel Co-chairs or writing group as is or are adapted from the selected guidelines.
- The full Panel reviews each recommendation and modifies them according to their level of agreement (acceptability and applicability)

Adaptation as part of a Submission by Another Organization

Organizations may submit guidelines for adaptation consideration by submitting the following to guidelines@asco.org:

1. Endorsement/adaptation Request Form
2. Copy of the guideline (published or unpublished)
3. Conflict of Interest Policy/procedures followed during development
4. Additional supporting documents as appropriate

At the time of submission, organizations may elect to pursue Adaptation as an option, in which changes to the recommendation(s) are acceptable, if needed.

Under the Adaptation option:

- Applicant organizations can indicate that revisions to recommendations are acceptable if deemed necessary by the ASCO Expert Panel and, in which case, an adaptation approach can be utilized. Edits could include the introduction of new evidence, revisions to existing recommendations, or additional recommendations offered by ASCO to further inform the ASCO membership.
- Guidelines undergo a less thorough triage process with this option. It is understood that a unanimous, strong agreement with the recommendations is not necessary among initial content expert reviewers.
- An update of the literature search will be performed.

Once a guideline is approved for adaptation, the original authoring organization and/or the copyright holder(s) is/are contacted for consent to proceed, and an ASCO expert panel is formed. An ASCO Expert Panel of approximately 10 volunteer members is formed to review a guideline to be considered for adaptation. The expert content reviewers are typically invited and at least one of the original guideline authors is invited to serve on the Expert Panel. Multidisciplinary content experts, patient representatives, community oncologists, and other topic-relevant health providers comprise the remainder of expert panel.
Guidelines considered for adaptation should be based on a systematic review. If the quality of the evidence identified through the systematic review is insufficient to inform recommendations, a consensus methodology may be utilized. There should be an explicit link between the evidence and the recommendations. Preferably, each recommendation will reflect the strength of the evidence and the strength of the recommendation. If consensus is used, a consensus methodology that limits the potential for bias (e.g. modified Delphi approach) is preferred. The guideline should report the conflict of interest procedures and the majority of expert panelists should be considered free from conflicts of interest. There should be no industry involvement of any nature supporting the development of the guideline.

As part of the organizational review and approval process, ASCO adaptations are reviewed independently of the expert panel by select members of the EBMC. The EBMC members present the results of the review to the full committee and the EBMC votes on whether to approve the draft as an ASCO guidance product.

ASCO adaptations are submitted to the original authoring organization and copyright holder for review and permission to reprint any copyright material. Guideline adaptations are then submitted for consideration of publication to the Journal of Clinical Oncology (JCO). Although editorial revisions may be made through the publication process, the adaptation format is written according to a specific journal template. Typically, the JCO publication contains the following information: title and the group responsible for development of the guideline, purpose and rationale, methods used, target population, adapted recommendations and commentary summarizing the ASCO perspective including any additions or modifications specific to the ASCO membership.

Derivative products such as slide sets, recommendations tables, and patient materials may be developed, and reprints are available for adaptation materials.

Updating procedures for all ASCO guideline products follow an established updating process (see ASCO’s Updating Policy and Procedures). If the need for an update is identified, ASCO staff will reach out to the originating guideline organization to assess their interest in updating the original guideline. If a guideline update is planned, ASCO may opt to wait for the guideline update or may release a provisional update until the guideline update is completed. If there are no plans to update the guideline, ASCO will undertake an update. ASCO will share the update evidence and recommendations with the originating guideline organization.
APPENDIX VI: ASCO Endorsement/Adaptation Request Form

Thank you for your interest in submitting your organization’s guideline for potential ASCO endorsement. ASCO will consider endorsing clinical practice guidelines developed by other guideline development organizations when relevant to the mission and interests of ASCO and its membership.

Please complete and e-mail the following documents to guidelines@asco.org.

- Endorsement Request Form
- Copy of the guideline
- Conflict of Interest Policy/procedures followed during development.
- Additional supporting documents as appropriate.

**Type of endorsement request (Please select option 1 or 2):**

1. ☐ Endorsement
   a. It is preferred that no revisions are made to the recommendations however discussion points, qualifying statements, or additional commentary may be added as part of the ASCO endorsement. It is understood that endorsement only requests preclude consideration of adaptation by ASCO.
   b. It is understood that fewer endorsement only requests will be selected for ASCO endorsement since there needs to be unanimous strong agreement with the recommendations among three initial content expert reviewers.

2. ☐ Endorsement or Adaptation
   a. Either endorsement or adaptations to the recommendations are acceptable, if needed. If recommendation changes are made, the product will be considered an adaptation rather than an endorsement. Discussion points, qualifying statements, or commentary may be added to the draft.
   b. It is understood that more endorsement or adaptation submissions will be selected for ASCO development since there does not need to be unanimous strong agreement with the recommendations among two initial content expert reviewers.

1. Organization: ________________________________________________________________
2. Staff Contact (Name and Email Address): __________________________________________
3. Title of the Guideline: _________________________________________________________
4. Journal Citation if applicable: __________________________________________________
5. Is this guideline based on a systematic review? ________________________________
6. Did industry involvement direct the development of the guideline? __________________
7. What years do the literature search span? ______________________________________
8. Can ASCO reproduce guideline copyright materials to accompany an endorsement? ______
9. Is an updating plan in place for this guideline? _________________________________

Are there other comments or details about this guideline that you would like to share?
____________________________________________________________________________________________
____________________________________________________________________________________________
____________________________________________________________________________________________

© American Society of Clinical Oncology 2021. All rights reserved. 28
APPENDIX VII: ASCO Expert Reviewer Content Review Form

Guideline Title: ________________________________
Reviewer Name: ________________________________
Organization: ________________________________

Background and Instructions. ASCO reviews clinical practice guidelines developed by other organizations for consideration of endorsement or, in some cases adaptation. As a content expert, you have been asked to provide a content review of a guideline that is under consideration by ASCO.

Please Note: The applicant guideline organization has requested that the attached guideline be considered for:

☐ Endorsement – no changes to the recommendations are requested, however revisions may include discussion points, clarifications, or qualifying statements for context, new evidence, etc.

☐ Endorsement or Adaptation – changes to the recommendations are acceptable if determined necessary by an ASCO expert panel. In addition to revisions that may include discussion points, clarifications, or qualifying statements for context, new evidence, etc., changes to the recommendations will result in an adaptation rather than an endorsement.

Please indicate your level of agreement that best applies for each of the following items.

<table>
<thead>
<tr>
<th>According to your understanding of the topic:</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall there are no substantive concerns with the methods used to develop this guideline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No important studies are missing from the summary of the evidence described in this guideline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The evidence described in this guideline was interpreted according to my understanding of the data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The recommendations in this report are clear and unambiguous</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The recommendations are consistent with the results of the evidence review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I agree with the recommendations in the guideline</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One or more recommendations require minor clarification that could be included in the discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>One or more recommendations require major revision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In your estimation, based on your level of agreement with the items above, do you feel this guideline should be considered by ASCO as (please pick one):

☐ Endorsement - the guideline recommendations would likely be endorsed as written.
☐ Endorsement or Adaptation – revisions may need to be made to the recommendations
☐ Not Considered for Endorsement or Endorsement or Adaptation

If this guideline is approved for endorsement or adaptation development as an ASCO guideline product, please note the capacity in which you’d like to potentially participate on the Expert Panel.

☐ Member
☐ Co-Chair
☐ I am not interested in participating on the panel

Are there other comments or details about this guideline that you would like to share?
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________________________________________________
_____________________________________________________

APPENDIX VIII: EVIDENCE BASED MEDICINE COMMITTEE: RESPONSIBILITIES AND AUTHORITIES

Volunteer Group: Evidence Based Medicine Committee
Reports to: Cancer Care Delivery Council
Departments: Policy
Staff: Division Director, Guidelines and Measurement

Purpose and Charge
To oversee the selection, prioritization, development, review, and approval of ASCO’s evidence-based cancer care products on behalf of the Board. Quality products include: Evidence Reviews, Clinical Practice Guidelines (both traditional and living*), Measures, and Standards. The Committee is mandated to oversee the selection, prioritization, development, and measurement of quality products to enhance the quality, organization, effectiveness, and appropriateness of cancer care and services, as well as support performance improvement from prevention through survivorship and end of life care.

* Living guidelines defined as topics developed using the methodology of multiple rapid evidence reviews that are used to inform a living guideline that is continuously updated.

Composition, Members’ Term and Appointment Process
The Committee is composed of up to 40 members, with academic and private practice representation, across a broad spectrum of cancer disease sites, as well as expertise in clinical trial design, guideline, measure and standards development and analysis. The Committee membership also includes members with expertise in medical oncology, radiation oncology, surgical oncology, resource-constrained settings, biostatistics, informatics, quality of life, health services researchers, care delivery experts, supportive care, survivorship, the organization of care/practice, measure development, quality improvement, performance analytics and the patient perspective. Other allied professions should be included as needed.

The Committee is composed of a) Committee leadership appointed by the American Society of Clinical Oncology Board of Directors (“the Society Board”), b) Society Board-appointed members, c) leadership of steering groups and task forces that report to the Committee, and d) various liaison positions. The Committee leadership is composed of the Chair-Elect, Chair, and the Immediate Past Chair. The Committee Chair-Elect shall be appointed by the Society Board of Directors and shall serve one-year consecutive terms as Chair-Elect, Chair, and Immediate Past Chair. The Chair-Elect may, but need not, be a Board-appointed Committee member already serving on the Committee or have just finished serving on the Committee. The Immediate Past Chair has the right of first refusal to serve as the Chair of the Methodology Subcommittee. The Committee leadership will also serve as members on the Cancer Care Delivery Council in their Committee leadership capacity. The leadership from the Measures Steering Group (Chair-Elect, Chair and Immediate Past Chair) and leadership of any task forces that are under the purview of the Committee will be ex-officio members of the Committee. Liaison positions on the Committee will include a Society Board Liaison, and the Committee leadership may also appoint liaisons to other volunteer groups, as needed.

Committee members, other than liaisons and ex-officio members, will be appointed by the Society Board of Directors, each to serve a three-year term. These Committee members may be re-appointed to serve one additional term on occasion with approval from the Board. All Committee members are voting members of the Committee. Any Committee member may be removed by the Society Board of Directors in its sole discretion.

The Committee may also include a liaison from the Society Board of Directors, from other ASCO Committees, volunteer groups and programs as needed as well as external liaisons, if needed.
Committee should not exceed 40 members (which includes Chair(s), Society Board Liaison, and other committee liaisons).

Committee Structure
The Committee may create subcommittees made up of a subset of Committee members to carry out specific tasks. The Committee leadership can also establish steering groups, task forces, advisory groups, and expert panels to address specific issues or to carry out ongoing specific programs. These volunteer groups under the Committee can include ad hoc subject matter experts and ASCO membership is desirable.

Committee Term
The duration of the Committee is up to the discretion of the Society Board of Directors. The term of any task forces established will vary dependent on the change and deliverable(s) but will not exceed a term of five years.

Responsibilities and Authorities

Committee:
- Prioritize and approve topics selected for evidence reviews, clinical practice guidelines (traditional and living), standards, measures, and other related projects as appropriate.
- Act as the approval body for evidence reviews, guidelines (traditional and living), standards, measures, and other related projects as appropriate.
- Review and approve items proposed by the Methodology Subcommittee.

Guideline Methodology Subcommittee:
- Provide recommendations to the Committee on quality product policies and processes.
- Review quality product development protocols if methodologic expertise and/or input required
- Perform additional duties as delegated by the Committee.

Chair:
- Disclose potential conflicts of interest and comply with applicable ASCO conflict of interest policies.
- Oversee the delegation of responsibility for evidence reviews, guidelines (traditional and living), measures, and standards development, and other related projects as appropriate.
- Follow Board-approved procedures for review and approval of evidence reviews, guidelines, measures, standards, and other related projects as appropriate.
- Oversee the delegation of identifying and prioritizing topics for product development and strategic assessment of needed quality products.
- In consultation with the Chair-Elect, Immediate Past Chair, and Board liaison, approve composition of expert panels charged with developing guidelines (traditional and living), standards, and other related quality projects as appropriate.
- In consultation with the Chair-Elect, Immediate Past Chair, and Board liaison, identify and approve ASCO representatives appointed to the guideline or standards panels of other organizations or appointments for other similar initiatives.

Chair-Elect:
- Disclose potential conflicts of interest and comply with applicable ASCO conflict of interest policies.
- In Chair’s absence, serve as Chair at Committee meetings.
Members:

- Assist the Chair in carrying out the mission and the objectives of the Committee.
- With the Chair, Immediate Past Chair, and Board liaison approve composition of expert panels charged with developing guidelines, standards, and other related projects as appropriate.

- Disclose potential conflicts of interest and comply with applicable ASCO conflicts of interest policies.
- Suggest guideline, measures, and standards topics, and other related projects as appropriate, for consideration by the Committee.
- Suggest potential Expert Panel, Advisory Group, and Steering Group members
- Review and approve guidelines (traditional and living), measures, standards, and other related projects as appropriate.
- Participate in Guideline Panels, Measures Technical Panels, Standards Panels, Advisory Groups, Steering Groups, and other associated groups of the Committee as requested by the Chair.

Staff:

- Disclose potential conflicts of interest and apply/implement applicable ASCO conflicts of interest policies.
- Conduct systematic reviews and draft documents relevant to guideline, measures, and standards development and other related projects as appropriate.
- Conduct evidence reviews and draft documents relevant to guidelines, measures, and standards development and other related projects as appropriate.
- Participate in the development of products related to guidelines, standards, and measures development, updating, dissemination, and implementation.
- Serve as resource in methodology and provide support to the Methodology Subcommittee, Expert Panels, Advisory Groups, and Steering Groups.
- Ensure consistent application of standardized format for guidelines, measures, standards, and other related projects as appropriate.
- Collate and edit revisions to the guidelines, measures, standards, and other related projects as appropriate.
- Ensure proper legal review of guidelines and standards and other related projects as appropriate.
- Be responsible for the assessment of new evidence and the timely updating of the guidelines, measures, and standards and other related projects as appropriate.
- Provide expert consultation to the Committee, to which the Board of Directors has granted authority to convene and oversee the substantive work of practice guideline, measures, and standards development.
- Support the independence of the guideline, measures, and standards development processes as well as other related projects as appropriate.
- Assist leadership of the Committee in supporting the development of guidelines measures, and standards and other related projects as appropriate.

Staff Support
Division Director of Guidelines Management and the Policy teams will primarily be supporting the work of the Committee.

Committee Meetings Calendar
The Committee will meet at least twice per year (virtually or in-person), once in the Spring and Fall. In-person meetings typically occur at ASCO Headquarters in Alexandria, VA. The Committee may also have ad-hoc meetings via teleconference calls and/or webinars throughout the year, as needed.
APPENDIX IX: PANEL COMPOSITION: EXPERT PANEL RESPONSIBILITIES AND AUTHORITIES

VOLUNTEER GROUP: Guideline Expert Panels
DEPARTMENT: Policy & Advocacy
DEPARTMENT STAFF: Guidelines Staff

PURPOSE
Guideline Expert Panels create clinical guidance on specific topics as prioritized by ASCO. ASCO develops clinical practice guidelines, provisional clinical opinions, guideline endorsements, standards, and guideline adaptations. These evidence-based clinical guidance products serve as a guide to outline appropriate methods of treatment and care for oncology health care practitioners, patients, and caregivers. Expert Panels report to the Evidence Based Medicine Committee (EBMC)

COMPOSITION OF EXPERT PANELS
Expert Panels include topic-specific content experts with an interdisciplinary focus (medical oncology, community oncology, radiation oncology, surgery, health services researchers, pathology, and other experts applicable to the topic). Expert Panels also have representation from the Practice Guidelines Implementation Network and at least one patient advocate or representative. Members of the EBMC and Guideline Advisory Groups (AGs) may also serve on the expert panels.

PANEL CO-CHAIR’S APPOINTMENT AND TERM
The EBMC Leadership (Chair, Chair-Elect, Immediate Past Chair, and Board Liaison), in consultation with the appropriate Guideline AG Co-Chairs, and at the discretion of ASCO, will typically appoint two Co-Chairs for each Expert Panel. Expert Panel Co-Chairs will serve a term of no more than three years; however, the EBMC Leadership may appoint panel co-chairs to additional terms on a case-by-case basis.

PANEL MEMBERS’ APPOINTMENT AND TERM
The Co-Chairs of each Expert Panel will recommend Expert Panel members to the EBMC Leadership. The EBMC Leadership is responsible for appointing Expert Panel Members at the discretion of ASCO. Expert Panel Members will serve a term of no more than three years; however, the EBMC Leadership may appoint panel members to additional terms on a case-by-case basis.

PANEL (CO-CHAIRS AND MEMBERS)
RESPONSIBILITIES AND AUTHORITY:
- Participate in drafting the protocol, systematic review, recommendations and other elements of clinical guidance
- Assist in dissemination and implementation efforts
- Provide guidance to the EBMC and Guideline AGs on updating and maintaining the guideline
- Provide guidance and reports to EBMC, Guideline AGs, and the ASCO Board as needed.
- Carry out other related activities as delegated by the EBMC.
- Assure meetings and discussions take place in an environment that welcomes opposing views and allows for evidence-based resolution of disagreements in a respectful manner.
- Acknowledge that participation on ASCO Expert Panels does not confer authority to speak or provide communication on behalf of ASCO without express permission from ASCO.
Confidentiality Policy and Disclosure of Potential Conflicts of Interest

- Must observe a strict policy of confidentiality of documents, draft and final, pending publication and are required to keep content of panel deliberations confidential.
- Must adhere to the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines by disclosing all conflicts of interest, including commitments that might be perceived as conflicts prior to initiating work on the guideline; and are asked to apprise ASCO staff of any changes that arise over the course of the project. Refrain from initiating new relationships with companies that may create a conflict under ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines for the duration of the panel term.

Panel Members

Responsibilities and Authority:

Role in the Development of the Systematic Review of the Literature and Formulation of Recommendations

- Collaborate with the ASCO Guidelines Co-Chairs and Staff to develop a systematic review.
- Substantively contribute to interpretation of the evidence in formulating guideline recommendations and other clinical guidance

Meeting Attendance and General Responsibilities

- Attend Expert Panel meetings to synthesize the results of the systematic review, discuss the structure of the guideline, and to formulate consensus recommendations. These meetings may be held face-to-face or via webinar.
- Be prepared for the meeting by reviewing the materials in advance.
- Meet deadlines for literature review, manuscript drafting, and manuscript editing within a reasonable timeframe.
- Panel members who are unable to adhere to the project timeline/work schedule are asked to notify ASCO staff and Panel Co-Chairs. They may be asked to resign to ensure the timely development of guideline product and to allow for recruitment of an alternate member to prevent an additional workload burden on the remaining panel members.

Manuscript Development, Guideline Authorship Policies, and Dissemination

- Actively participate in the development of recommendations
- Critically edit and review drafts.
- Panel members who have attended meetings, participated in the review of evidence and helped draft and edit the guideline are eligible to serve as authors on the published product provided they meet ASCO’s journal authorship policies.
- Upon request, participate in, or provide feedback on, the development of clinical tools and resources such as summary tables, charts or pocket cards designed to facilitate implementation into practice.
- Upon request, review measures developed from the recommendations for use as quality indicators.

Role in Guideline Updates

- At the discretion of the EBMC Leadership, panel members may be invited to serve on an update panel after publication. Regular reviews of guidance recommendations may identify the need for an update. In this case, the Panel may reconvene to discuss whether an update is appropriate. Panel members are expected to participate in the meetings and to volunteer literature that may expedite the update process.
PANEL CO-CHAIRS
RESPONSIBILITIES AND AUTHORITY

Role in the Conduct of the Systematic Review of the Literature
• Work with ASCO staff in development of the protocol, which includes specific criteria for project development, the systematic review, and timelines.
• Plan a strategy for the Panel to complete and review the results of the systematic review, as well as a plan for the formulation of recommendations. They assume responsibility for deciding what components of the work can be completed in-person versus via electronic communication or conference calls.

Meeting Attendance and General Responsibilities
• Depending on the scope of the project, Panel co-chairs may hold regular meetings with ASCO staff (outside of the full Panel meeting) in order to move the project to completion.
• As the leaders of the effort, Co-Chairs are expected to meet the commitments and timelines that they establish at the onset of the project during protocol development.

Manuscript Development, Guideline Authorship Policies, and Dissemination
• Assume primary responsibility for drafting the manuscript, but may divide the work by having specific panel members draft sections. It is recommended that no more than three to four people assume responsibility for initially drafting the manuscript.
• Typically serve as first and last authors of the finished product, although there can be exceptions to this at the discretion of the Co-Chairs.
• Determine order of authorship.
• All authorship determinations must meet ASCO journals’ requirements for authorship.
• At ASCO’s explicit invitation in each instance, they may interface with the media at the time of publication and assist ASCO in the development of press releases, materials suitable for use with patients, and publication on the cancer.net website. Co-Chairs are not expected to draft these documents, but to critically review them to ensure that the content is accurate and clear.
• Upon request, provide feedback regarding or input into the development of clinical tools and resources such as summary tables, charts or pocket cards that are designed to facilitate implementation into practice.
• Upon request, review measures developed from the recommendations for use as quality indicators.

Role in Guideline Updates
• With ASCO Staff assistance, decide when to reconvene the panel and have responsibility for updating the guideline recommendations and for developing the manuscript that results from any changes to these recommendations.
• With assistance from ASCO Staff, responsible for reviewing a set of abstracts from an updated literature search to identify potentially practice-changing data based on defined criteria (see description of “signals” option for updating guidelines in the Guideline Procedures Manual). These data represent “signals” for updating a guideline.

STAFF
RESPONSIBILITIES AND AUTHORITY:

Administrative Support
• Coordinate meetings and conference calls for Panel members.
• Coordinate mailing both traditional and electronic of documents/manuscripts that require review
• Coordinate adherence to a timeline by helping with scheduling and reminders.
• Manage references, confirm guideline references through electronic databases for accuracy and completeness, and obtain articles, compile and distribute as appropriate.
• Field inquiries regarding the ASCO Clinical Practice Guideline Program, and other related information from members
• Special project management when necessary
• Assist the Co-Chairs with meeting organization, the development and preparation of meeting agendas and reports, maintenance of responsibilities, and evaluation of materials.
• Manage Conflicts of Interest disclosures

**Systematic Review/Methodological Support**
• Coordinate the conduct of literature searches, systematic literature reviews, and meta-analyses as needed
• Monitor published literature and coordinate updating schedules
• Facilitate adherence to ASCO policy and procedure on guideline development

**Editorial Support**
• Contribute to the editing of documents
• Maintain standardized formatting of products
• Collate and assemble revisions submitted by Panel members
• Coordinate communication with ASCO media affairs
• Coordinate communication with ASCO staff in the development of patient materials, office practice tools and web-based versions, power point summaries, etc.

**General EBMC and Subcommittee Support**
• Provide status reports to the EBMC and the Board as needed
• Attend Expert Panel and Working Group meetings and serve as primary staff liaison to Expert Panels and Working Groups
• Assist the EBMC in developing a program of guideline implementation and evaluation strategy
• Ensure proper legal review of guidelines
• Monitor all conflict of interest statements for Committee and Panel members
• Facilitate adherence to ASCO policies and procedures on authorship and conflict of interest

**Panel Calendar**
The Expert Panels will meet on an as needed basis.
APPENDIX X: PROTOCOL WORKSHEET

ASCO GUIDELINES

ASCO CLINICAL PRACTICE PROTOCOL WORKSHEET <insert title>: American Society of Clinical Oncology Clinical Practice Guideline (or Guideline Update)

A. Title of Guideline
   <insert title>: ASCO Guideline (or Guideline Update)

B. Expert Panel Membership

<table>
<thead>
<tr>
<th>Name</th>
<th>Geographic Location Including International</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sub-specialty</td>
<td>(e.g. Pacific West, West, Central, Mid-West, Mid-South, North East, Mid Atlantic, South East, Canada, Germany, Mexico)</td>
</tr>
<tr>
<td>Email</td>
<td></td>
</tr>
<tr>
<td>Institution</td>
<td></td>
</tr>
<tr>
<td>State/Province/District</td>
<td></td>
</tr>
</tbody>
</table>

(Indicate Co-Chairs and preference for First and Last)

<table>
<thead>
<tr>
<th>Medical Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radiation Oncology</td>
</tr>
<tr>
<td>Surgical Oncology</td>
</tr>
<tr>
<td>Community Oncology (PGIN Representative)</td>
</tr>
<tr>
<td>Other Disciplines (as needed)</td>
</tr>
<tr>
<td>Patient Representatives</td>
</tr>
<tr>
<td>Organizational Representatives</td>
</tr>
</tbody>
</table>
C. **Overarching Guideline Question**

Guideline question: 

D. **Overarching Inclusion Criteria** (criteria that would apply to all research questions)

Inclusion Criteria: 

E. **Overarching Exclusion Criteria** (criteria that would apply to all research questions)

Exclusion Criteria: 

F. **Definition of Terms**

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

G. **Searching the Literature**

Generally speaking, only the top three tiers of evidence should be considered in an ASCO guideline product to make strong evidence-based recommendations (this includes evidence-based practice guidelines from other guideline development organizations). Inclusion of evidence below that threshold should be justified with a compelling rationale (e.g. inclusion of cohort studies for diagnostic utility guidance) and generally should be followed by lower strength recommendations.
### Question 1

<table>
<thead>
<tr>
<th>Research Question:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population:</td>
</tr>
<tr>
<td>Intervention:</td>
</tr>
<tr>
<td>Comparison:</td>
</tr>
<tr>
<td>Outcomes:</td>
</tr>
<tr>
<td>• Critical</td>
</tr>
<tr>
<td>• Important but not critical</td>
</tr>
<tr>
<td>• Of limited importance</td>
</tr>
<tr>
<td>Time:</td>
</tr>
<tr>
<td>Health setting:</td>
</tr>
<tr>
<td>Study designs:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Publication date from: to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Languages:</td>
</tr>
</tbody>
</table>

**Study Selection Criteria:** (applies only to this research question)

- Inclusion Criteria:
- Exclusion Criteria:

**Concepts:**

**Evidence sources:**

- PubMed:
- Cochrane:
- GIN:
- ECRI:
- AiCPG:
- Other (specify):
- Other (specify):
## Question 2

<table>
<thead>
<tr>
<th>Research Question:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Population:</td>
<td></td>
</tr>
<tr>
<td>Intervention:</td>
<td></td>
</tr>
<tr>
<td>Comparison:</td>
<td></td>
</tr>
<tr>
<td>Outcomes:</td>
<td></td>
</tr>
<tr>
<td>• Critical</td>
<td></td>
</tr>
<tr>
<td>• Important but not critical</td>
<td></td>
</tr>
<tr>
<td>• Of limited importance</td>
<td></td>
</tr>
<tr>
<td>Time:</td>
<td></td>
</tr>
<tr>
<td>Health setting:</td>
<td></td>
</tr>
<tr>
<td>Study designs:</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Publication date from:</th>
<th>to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Languages:</td>
<td></td>
</tr>
</tbody>
</table>

**Study Selection Criteria:** (applies only to this research question)
- **Inclusion Criteria:**
- **Exclusion Criteria:**

<table>
<thead>
<tr>
<th>Concepts:</th>
</tr>
</thead>
</table>

**Evidence sources:**
- PubMed:
- Cochrane:
- GIN:
- ECRI:
- AiCPG:
- Other (specify):
- Other (specify):
**Question 3**

**Research Question:**

| Population: |  |
| Intervention: |  |
| Comparison: |  |
| Outcomes: |  |
| • Critical |  |
| • Important but not critical |  |
| • Of limited importance |  |
| Time: |  |
| Health setting: |  |
| Study designs: |  |

**Publication date from:** to:

| Languages: |  |

**Study Selection Criteria:** (applies only to this research question)

| Inclusion Criteria: |  |
| Exclusion Criteria: |  |

**Concepts:**

**Evidence sources:**

| PubMed: |  |
| Cochrane: |  |
| GIN: |  |
| ECRI: |  |
| AiCPG: |  |
| Other (specify): |  |
| Other (specify): |  |
### Question 4

<table>
<thead>
<tr>
<th>Research Question:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population:</td>
</tr>
<tr>
<td>Intervention:</td>
</tr>
<tr>
<td>Comparison:</td>
</tr>
<tr>
<td>Outcomes:</td>
</tr>
<tr>
<td>• Critical</td>
</tr>
<tr>
<td>• Important but not critical</td>
</tr>
<tr>
<td>• Of limited importance</td>
</tr>
<tr>
<td>Time:</td>
</tr>
<tr>
<td>Health setting:</td>
</tr>
<tr>
<td>Study designs:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Publication date from:</th>
<th>to:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Languages:</td>
<td></td>
</tr>
</tbody>
</table>

**Study Selection Criteria:** (applies only to this research question)

<table>
<thead>
<tr>
<th>Inclusion Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exclusion Criteria:</td>
</tr>
<tr>
<td>Concepts:</td>
</tr>
</tbody>
</table>

**Evidence sources:**

<table>
<thead>
<tr>
<th>PubMed:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cochrane:</td>
</tr>
<tr>
<td>GIN:</td>
</tr>
<tr>
<td>ECRI:</td>
</tr>
<tr>
<td>AICPG:</td>
</tr>
<tr>
<td>Other (specify):</td>
</tr>
<tr>
<td>Other (specify):</td>
</tr>
</tbody>
</table>
H. Timeline

<table>
<thead>
<tr>
<th>Development Step</th>
<th>Target Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protocol &amp; Planning</td>
<td></td>
</tr>
<tr>
<td>Systematic Review draft completed</td>
<td></td>
</tr>
<tr>
<td>Second Panel Meeting – Draft recommendations</td>
<td></td>
</tr>
<tr>
<td>Revisions to Manuscript Draft</td>
<td></td>
</tr>
<tr>
<td>Open Comment</td>
<td></td>
</tr>
<tr>
<td>Panel Approval</td>
<td></td>
</tr>
<tr>
<td>Internal &amp; EBMC Review</td>
<td></td>
</tr>
<tr>
<td>Final report with revisions completed</td>
<td></td>
</tr>
<tr>
<td>Manuscript Submission to JCO</td>
<td></td>
</tr>
<tr>
<td>Manuscript Publication</td>
<td></td>
</tr>
</tbody>
</table>

I. Additional topics for discussion (no formal literature search to be performed)


J. List of Affected Companies

<table>
<thead>
<tr>
<th>Class of drug</th>
<th>Agent (generic/trade)</th>
<th>Affected company</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Date search for affected companies completed: ______________________
APPENDIX XI: CONSENSUS METHODOLOGY

The decision to use formal consensus for one or more recommendations in a guideline generally occurs following completion of the literature search for the systematic review and the evidence is limited, inconsistent, indirect, or of poor quality. While the decision to incorporate consensus recommendation(s) may vary, the common thread is recommendations are needed to inform clinical practice however there is lack of sufficient evidence. Table 1 provides an abbreviated depiction of the modified Delphi consensus process.

Participants

Steering Committee

A Steering Committee, including the Expert Panel Co-chairs and one or two additional panel members, is formed for any guideline that will include formal consensus. For guideline topics relevant to multiple specialty areas, the Steering Committee should include representatives from other specialties if possible.

Consensus Group

The consensus group includes all Expert Panel members who are not members of the Steering Committee, as well as other subject-matter experts and community-based practitioners. Sources for potential members include experts who could not participate in the Expert Panel, members of ASCO’s Practice Guideline Implementation Network (PGIN), and members of other ASCO Committees, particularly the Clinical Practice Committee. The suggested target number of participants in the Consensus Group is between 30 and 40. Participation of non-physicians will be considered on a case-by-case basis.

Table 1. Consensus-Based Guidance Process based on a Modified Delphi Approach

| Generate Draft Recommendations | 1. Define clinical questions, comparisons of interest - Steering Committee (SC) |
|  | 2. Conduct systematic review of the literature - ASCO Staff |
|  | 3. Draft consensus recommendation(s) and clinical rationale - SC |
|  | 4. Formulate Consensus Group - ASCO Staff |
|  | 6. Revise consensus recommendations - EP |
|  | 7. Approve sending draft recommendations to the Consensus Group. |
| Consensus Round One, Ratings | 8. Obtain anonymous ratings, written feedback - Consensus Group (CG) |
|  | 9. Compile ratings and comments – ASCO Staff |
| Consensus Round One, Review Results | 10. Ratings that meet pre-defined threshold for consensus are accepted - SC |
|  | a. A minimum of 75% is required for consensus; a higher threshold may be prospectively defined by the Steering Committee or Panel |
|  | b. Only changes to recommendation content are returned to the Consensus Group for additional rating rounds |
|  | 11. If consensus was not achieved, recommendations are revised with particular attention to comments from the Consensus Group – SC |
|  | a. The Panel may be consulted when rewriting recommendations |
Consensus Round Two, Ratings

12. Consensus recommendations are sent to the Consensus Group – ASCO Staff
   a. Both new and the previous iteration of recommendations are presented
   b. Recommendations with style or wording modifications may be sent for rating, though this is not required

13. Ratings and comments are compiled – ASCO Staff

Review Results and Evaluation of Consensus

14. Ratings are accepted if consensus is achieved.
   a. Revisions to style or wording are accepted based on a simple majority.

15. If consensus has still not been achieved, the recommendation can again be rewritten, or left unanswered

\(^a\) Consensus Group includes Expert Panel Members and ~20-25 other members, such as subject matter experts or community-based practitioners. Creation of the Consensus Group follows ASCO COI policy.

\(^b\) Percent agreement is based on the number of individuals that respond with either “strongly agree” or “agree” on either a five- or seven-point Likert scale; where “strongly agree” rated as a one and “strongly disagree” rated as a five.

Conflict of Interest Policy

Consensus Group invitees will be asked to complete the same disclosure form that prospective members of an Expert Panel complete. The requirement for an unconflicted majority, noted in ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines, also applies to the Consensus Group.

Recommendation Development

Drafting Consensus Recommendations and Clinical Considerations

The Expert Panel is responsible for developing preliminary consensus recommendations a summary of any included evidence, and clinical considerations for each of the consensus recommendations. The evidence and clinical considerations document describe the underlying logic or justification for a given recommendation. A Consensus Group then rates their agreement with each of the recommendation statements using a ratings form for Round One.

The Expert Panel will revise any consensus recommendation with substantive lack of agreement and/or feedback from the Consensus Group. Recommendations that do not receive 75% consensus agreement are revised before the Consensus Group begins another round of ratings.

Expert Panel Meeting

Draft consensus recommendations and clinical considerations are presented at the panel meeting. Discussion of supporting evidence (e.g., epidemiologic data, clinical experience, trial data of study designs excluded from the systematic review) among Expert Panel members may require modification of either the draft consensus recommendations and/or the clinical considerations. Both are updated, as necessary, before sending materials to the Consensus Group for the Consensus Rating.

Rating of Recommendations
Members of the Consensus Group are asked to rate their agreement with each consensus recommendation on a five- or seven-point Likert scale ranging from strongly agree to strongly disagree, as depicted in Table 2 (lower score corresponds with a higher agreement). The rating form includes additional space for raters to provide free-text comments. Each round of ratings is referred to as a Consensus Round.

**Table 2. Round One Rating Form Example**

<table>
<thead>
<tr>
<th>Clinical Question</th>
<th>Strongly Agree</th>
<th>Agree</th>
<th>Neither Agree nor Disagree</th>
<th>Disagree</th>
<th>Strongly Disagree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Consensus Recommendation Text</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

For subsequent rounds, Consensus Group members are provided with the previous iteration of the recommendation and the ratings distribution, along with the revised recommendation, as depicted in Table 3. Modifications to text style (bold, italics) may be made to highlight changes in the recommendation language. Consensus Group members are again asked to rate their level of agreement with the recommendation text on a five-point Likert scale.

**Table 3. Subsequent Rounds Rating Form Example**

<table>
<thead>
<tr>
<th>Clinical Question</th>
<th>Rating Frequency</th>
<th>Percent Agree</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous iteration</td>
<td>Agree → Disagree</td>
<td>1 2 3 4 5</td>
<td>10 10 5 5 0</td>
</tr>
<tr>
<td>Updated recommendation text</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Assessment of Ratings**

**Collection of Ratings Data**

Ratings will be collected from Consensus Group members either by sending individual emails to each member of the group or an online survey tool.

**Review of Ratings**

The percent agreement and median score for each question is calculated, as is the overall response rate. The percent agreement refers to the number of raters who indicated either “agree” or “strongly agree” divided by the total number of raters for the round. Non-responders are not included in the denominator. A frequency table depicting the collective ratings is then prepared for review by the Steering Committee, as in Table 4. Free-text comments from the Consensus Group members are also compiled into a single document, organized by question. The Steering Committee then meets to discuss results from the Consensus Group ratings and make revisions accordingly.
Table 4. Results - Round One Example

<table>
<thead>
<tr>
<th>Clinical Questions</th>
<th>Score Frequency (all N=31)</th>
<th>% Agree</th>
<th>Median</th>
</tr>
</thead>
<tbody>
<tr>
<td>(1) Question</td>
<td>15  13  1  1  1</td>
<td>90.3</td>
<td>2</td>
</tr>
<tr>
<td>(2) Question</td>
<td>11  16  2  2  0</td>
<td>87.1</td>
<td>2</td>
</tr>
</tbody>
</table>

Defining Consensus

Threshold for Adoption of a Consensus Recommendation

Compiled ratings from a Consensus Round must meet a minimum threshold in order for a recommendation to be adopted, listed below. The Expert Panel should prospectively determine if the consensus threshold for a given recommendation or set of recommendations is to be higher than the minimum listed below.

- **Strong Consensus**: If ≥90% of the respondents from the Consensus Group rate a recommendation as either “strongly agree” or “agree” and the median score is 1, the recommendation is adopted.
  - This assumes that “strong agreement” on the Likert scale is scored as a one.
  - Only “strongly agree” and “agree” are included in the percent agreement calculation
  - If a 7-point Likert scale is utilized, “minimally agree” is not considered in the percent agreement, only “strongly agree” or “agree”

- **Consensus**: If ≥75% and <90% of the respondents from the Consensus Group rate a recommendation as either “strongly agree” or “agree” and the median is either 2 or 1, the recommendation is adopted.

- **No Consensus**: If consensus is not achieved following two rounds of ratings, then the Steering Committee may opt to leave a clinical question unanswered and state, “Consensus could not be achieved.”

Revising Recommendations

Content Modifications

Following the first round of ratings, the Steering Committee must revise consensus recommendations that do not meet the pre-defined threshold criteria. Free-text comments from the Consensus Group are carefully considered when making revisions. The Steering Committee chooses whether to solicit input from the Expert Panel when redrafting consensus recommendation. The Expert Panel must be consulted if the Steering Committee chooses to revise the recommendation following two unsuccessful consensus rounds. The alternative is to leave the clinical question unanswered.

Style Modifications

The Steering Committee may modify either the style or language of the recommendation, without changing the content of the recommendation. The Steering Committee can, but is not required, query the Consensus Group to determine which option is preferred. Raters are simply asked which iteration they prefer, and a simple majority determines which recommendation text is included in the guideline.
APPENDIX XII: GRADE APPROACH FOR RATING CERTAINTY OF EVIDENCE AND STRENGTH OF RECOMMENDATIONS

Section 1: Certainty of Evidence
The quality of evidence is first assessed for each patient-important outcome, then an overall quality of evidence is determined across outcomes. There are four grades used to delineate the quality of evidence: high, moderate, low, and very low.

There are several factors determining the quality of evidence.9 Factors that can reduce the quality of evidence by one or two levels include risk of bias, inconsistency of results, indirectness of evidence, imprecision, or publication bias. Factors that can increase the quality of evidence by one level include the dose-response gradient, effect of plausible residual confounding. A large magnitude of effect may also increase the quality of evidence by one or two levels. As the evidence ratings are a continuum, decisions about upgrading or downgrading the quality are made in the context of other judgements. Additional details about each of these elements is provided:

Step 1: Assess the Quality of Evidence for Each Outcome

- 1.1 Review study design
  - Randomized trials provide high quality evidence
  - Observational studies provide low quality evidence
  - Limitations or special strengths can result in upgrading or downgrading of the evidence

- 1.2 Review factors that can reduce the quality of evidence
  - Risk of bias10
    - Evaluate the risk of bias11 by assessing the study limitations
  - Inconsistency of results12
    - Inconsistency in effect size of relative measures; risk ratios and hazard ratios without explanation
  - Indirectness of evidence13
    - Assess applicability of evidence if there are differences in populations, interventions, surrogate outcomes, or indirect comparisons
  - Imprecision14
    - Consider the boundaries of the confidence interval, and if the recommendation would change if the upper or lower boundary represented the true effect.

---

Assess the optimal information size

- Publication bias\(^{15}\)
  - Consider extent of uncertainty of the magnitude of the effect due to study design, study size, lag bias, search strategy, and asymmetry in funnel plot

1.3 Review factors that can increase quality of evidence\(^{16}\)

- Large magnitude of effect
  - Observational studies with no other limitations may be increased one level due to a large magnitude of effect (RR > 2 or < 0.5), or two levels due to a very large magnitude of effect (RR > 5 or < 0.2)

- Dose-response gradient
  - May increase confidence in the findings of observational studies

- Effect of plausible residual confounding
  - If all plausible residual confounders would result in an underestimate of the effect, the actual effect may be larger than data suggest

Step 2: Rating the Overall Quality of Evidence\(^{17}\)

Review the quality of evidence for each pre-specified critical outcome. If the quality rating is the same for each outcome, the same is true for the overall quality of evidence. If the quality rating differs, the lowest quality of evidence for any critical outcome determines the overall quality. Exceptions may apply if an outcome becomes irrelevant or not necessary.

Section 2: Strength of Recommendations

Guideline recommendations fall along a continuum depicted below; the strength of recommendations fall into two categories: strong and weak.\(^{18}\)

<table>
<thead>
<tr>
<th>Strength of Recommendation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strong</td>
<td>A strong recommendation implies that most or all individuals will be best served by the recommended course of action.</td>
</tr>
<tr>
<td>Weak</td>
<td>A weak recommendation implies that not all individuals will be best served by the recommended course of action. There is a need to consider more carefully than usual the individual patient’s circumstances, preferences, and values.</td>
</tr>
</tbody>
</table>


© American Society of Clinical Oncology 2021. All rights reserved. 51
When there are weak recommendations caregivers need to allocate more time to shared decision making, making sure that they clearly and comprehensively explain the potential benefits and harms to a patient.

Additionally, recommendations to use interventions only in research may be made, or no recommendation can be made by a panel. Expert Panels may also choose to issue good practice statements. These statements represent the guideline panel’s view of optimal practice, but are not graded.\textsuperscript{19} Panels should use good practice statements when high quality indirect evidence is available, but it would not be a good use of the panel’s limited resources to conduct formal evidence summaries. These good practice statements should be used sparingly.\textsuperscript{20}

To determine the strength and direction of recommendations, guideline panels assess several factors within four domains to indicate their certainty, included below.\textsuperscript{21} Generally, when the certainty of evidence is low or very low, the GRADE approach discourages guideline panels from making strong recommendations.

<table>
<thead>
<tr>
<th>Domain</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance between desirable and undesirable outcomes (trade-offs) taking into account: best estimates of the magnitude of effects on desirable and undesirable outcome importance of outcomes (estimated typical values and preferences)</td>
<td>The larger the differences between the desirable and undesirable consequences, the more likely a strong recommendation is warranted. The smaller the net benefit and the lower certainty for that benefit, the more likely a weak recommendation is warranted</td>
</tr>
<tr>
<td>Confidence in the magnitude of estimates of effect of the interventions on important outcomes (overall quality of evidence for outcomes)</td>
<td>The higher the quality of evidence, the more likely a strong recommendation is warranted</td>
</tr>
<tr>
<td>Confidence in values and preferences and their variability</td>
<td>The greater the variability in values and preferences, or uncertainty about typical values and preferences, the more likely a weak recommendation is warranted</td>
</tr>
<tr>
<td>Resource use</td>
<td>The higher the costs of an intervention (the more resources consumed), the less likely a strong recommendation is warranted</td>
</tr>
</tbody>
</table>

\textsuperscript{19} Guyatt GH, Schünemann HJ, Djulbegovic B, Akl EA. Guideline panels should not GRADE good practice statements. J Clin Epidemiol. 2015 May; 68 (5) 597-600


APPENDIX XIII: OPTIONS FOR COLLABORATION: ASCO REPRESENTATIVE REQUEST FORM

In order to facilitate the nomination of ASCO representatives for organizations’ guideline panels, please complete this form and submit it to guidelines@asco.org.

PLEASE BE ADVISED: Requesting or receiving a representative for a guideline panel IS NOT an endorsement of the guideline or of the requesting organization by ASCO. ASCO does not review or approve guidelines as a result of nominating representatives unless a separate endorsement or joint development agreement is in place. Please contact ASCO if your organization wishes to consider joint development or endorsement of a guideline.

Name:
Title:
Organization:
Email:

1. Guideline Title:

2. Number of ASCO representatives requested:

3. Please note the type of expertise or subspecialty requested (e.g. Medical oncologist with expertise in breast cancer specializing in young adults):

4. Please list any geographic preferences (e.g. within the USA, international, or specific geographical locations):

5. Is travel anticipated? If so, are travel costs covered by your organization?

6. Please indicate any known limitations that would preclude a nominated representative from participating on this guideline, such as specific disclosures.

7. Suggested Representatives (Optional). Please note, while suggested representatives will be considered, it is not a guarantee of nomination by ASCO.

Name:
Specialty:
Institution:
Email:
8. Please provide a short summary on the guideline topic.
APPENDIX XIV: OPTIONS FOR COLLABORATION: JOINT GUIDELINES

ASCO Guidelines

ASCO welcomes the opportunity to collaborate in the development of evidence-based clinical practice guidelines. Collaborative guidelines are intended to minimize duplication of effort, increase guideline production, and harmonize recommendations for the benefit of oncology professionals and patients. ASCO develops guidelines with other organizations under one of two models:

**ASCO Leads**
- ASCO collaborates with one or more organizations that take a participating role.
- Topic has been scheduled for development via ASCO’s regular topic selection and prioritization process.
- ASCO provides the resources to support developing the guideline, such as its own staff support, research, and financial support for volunteers to attend guideline panel in-person meeting(s). Participating organizations pay their own costs related to their participation in the guideline, such as their own staffing, review, approval and publication requirements.
- The guideline development process follows ASCO’s methodology, policies and procedures.
- The conflict of interest process follows ASCO’s policy.

**ASCO Joins**
- Another organization leads the guideline development and ASCO takes a participating role.
- Topic is not under development by ASCO or planned for ASCO development within the next year.
- Lead organization provides funding and staff support. ASCO may commit in-kind support such as meeting space toward completion of the effort.
- Development process meets systematic review-based methodology and guideline development transparency standards.
- Lead organization guideline panel is multidisciplinary and includes diverse expertise and experience, along with patient representation.
- Conflict of interest and funding policies meet CMSS Code standards for independence and transparency.

This document lays out criteria that apply to the second model, “ASCO Joins.”

**Guideline Development Methodology**
ASCO is pleased to consider invitations to join guidelines that are currently in development or slated for development if the following criteria are met:
- The lead organization is an established developer of high-quality clinical practice guidelines and/or shows a commitment to a rigorous and independent process for guideline development.
- Guideline Panels are multidisciplinary and include diverse expertise and experience, including patient representation, related to the topic.
- Guideline recommendations are actionable and clearly presented.
- Guidelines are developed using a systematic review-based method.
- Evidence is quality appraised.
- Recommendations reflect the strength of the evidence as well as the strength of the recommendation.
- Consensus recommendations will be considered only if a lack of suitable evidence was identified in the course of the systematic review.
• Other aspects of the collaboration, including authorship and publication, are set out in a Memorandum of Understanding.

Conflict of Interest Disclosure and Management
In a joint development effort, ASCO will follow the lead organization’s conflict of interest procedures as long as the organization has a written Conflict of Interest Policy in place that meets the requirements of the CMSS Code as they relate to guideline development. Guideline provisions of CMSS Code include:

• Guideline panel members, contributors and reviewers must disclose potential conflicts of interest before and during guideline development.
  o Disclosures of panel members must be provided to ASCO for consideration prior to ASCO joining a guideline and when changes occur.
• Speaker’s bureau, ownership above a set amount, or employment with an affected company by any Panel Member precludes ASCO’s participation in joint guideline development.
• All disclosures must be published in conjunction with the guideline.
• A majority of Guideline development panel members must be free of conflicts of interest relevant to the subject matter of the guideline.
• The panel Chair, or at least one Co-Chair, must be free of conflicts of interest relevant to the subject matter of the guideline and remain free for one year after publication.

If the lead organization does not have a conflict of interest policy or its policy does not conform to the CMSS Code, ASCO’s Conflict of Interest Policy Implementation for Clinical Practice Guidelines policy and procedures will apply to the entire guideline development process.

Financial Independence
For ASCO to join a guideline initiative, the project must meet the financial independence and transparency standards of the CMSS Code. These include:

• No organization participating in the joint guideline will accept direct financial support from for-profit health care companies for initial development of the guideline or for guideline updates.
  o Support from non-profit foundations (other than the foundations of for-profit health care companies), government bodies, or individuals is acceptable as long as the supporter does not have the ability to influence the guideline (see next bullet).
• Guideline development must be independent from influence of funding sources. Independence from funding sources means that the funders do not have any ability to influence topic selection, prioritization or timing of topic development, clinical questions to be addressed, panel composition, review of drafts, publication, or any content of the guideline.

Approval
Once the Expert Panel approves the guideline draft, each participating organization will follow their own guideline review and approval process within a mutually agreed upon time.

Publication
ASCO guidelines are submitted to the Journal of Clinical Oncology and the Journal of Oncology Practice for consideration of publications, any exceptions must be outlined in a Memorandum of Understanding.
APPENDIX XV: ADDITIONAL SAMPLE TABLES AND FIGURES

QUOROM Diagram

Inclusion criteria:
✓ Insert here
✓ Insert here
✓ Insert here

xx potentially relevant abstracts were

Exclusion criteria:
✗ Insert here
✗ Insert here

xx papers selected for full-text review

Meeting abstracts searched from (insert sources) did not show any relevant new abstracts (if

Expert consultation did not add any new relevant papers (if relevant)

xx papers reviewed in full-text

XX papers were excluded:
• xx papers showed little or no relevant information and were excluded
• xx papers did not report specifically on xx and were excluded
• insert others

xx papers had data extracted
### Cost

<table>
<thead>
<tr>
<th>Agent</th>
<th>Dose</th>
<th>Schedule</th>
<th>Price Per Dose (USD)</th>
<th>Total Cost Per Treatment Cycle (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>5-HT&lt;sub&gt;3&lt;/sub&gt; receptor antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ondansetron IV</td>
<td>8 mg /0.15 mg/kg</td>
<td>Prechemotherapy, one dose</td>
<td>1.10</td>
<td>1.10</td>
</tr>
<tr>
<td>Ondansetron oral (generic)</td>
<td>8 mg</td>
<td>Twice daily on days 1-3</td>
<td>6.50</td>
<td>6.50</td>
</tr>
<tr>
<td>Ondansetron oral (brand)</td>
<td>8 mg</td>
<td>Twice daily on days 1-3</td>
<td>45.55</td>
<td>268.28</td>
</tr>
<tr>
<td>Ondansetron oral dissolving tablet (generic)</td>
<td>8 mg</td>
<td>Every 12 hours as needed, days 1-3</td>
<td>6.50</td>
<td>6.50</td>
</tr>
<tr>
<td>Ondansetron oral dissolving tablet (brand)</td>
<td>8 mg</td>
<td>Every 12 hours as needed, days 1-3</td>
<td>85.05</td>
<td>253.14</td>
</tr>
<tr>
<td>Ondansetron oral soluble film (brand)</td>
<td>8 mg or 1 mg or 0.01 mg/kg IV</td>
<td>Every 12 hours as needed, days 1-3</td>
<td>75.82</td>
<td>225.46</td>
</tr>
<tr>
<td>Granisetron IV</td>
<td>1 mg or 0.01 mg/kg IV</td>
<td>Prechemotherapy, one dose</td>
<td>3.13</td>
<td>3.13</td>
</tr>
<tr>
<td>Granisetron oral</td>
<td>1 mg</td>
<td>Once (2 mg) on day 1, 1 mg twice daily on days 2, 3</td>
<td>6.50</td>
<td>14.36</td>
</tr>
<tr>
<td>Granisetron transdermal</td>
<td>3.1 mg</td>
<td>Prechemotherapy, up to 7 Days</td>
<td>467.00</td>
<td>467.00</td>
</tr>
<tr>
<td>Granisetron extended-release injection, for subcutaneous use†</td>
<td>10 mg</td>
<td>Prechemotherapy, and not more frequently than once every 7 days</td>
<td>467.00</td>
<td>467.00</td>
</tr>
<tr>
<td>Dolasetron oral</td>
<td>100 mg</td>
<td>Once daily on days 1-3</td>
<td>100.83</td>
<td>330.50</td>
</tr>
<tr>
<td>Palonosetron IV</td>
<td>0.25 mg</td>
<td>Prechemotherapy, one dose</td>
<td>228.80</td>
<td>228.80</td>
</tr>
<tr>
<td><strong>NK&lt;sub&gt;1&lt;/sub&gt; receptor antagonists</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aprepitant oral</td>
<td>125 mg</td>
<td>Prechemotherapy, one dose</td>
<td>284.01</td>
<td>284.01</td>
</tr>
<tr>
<td>Aprepitant oral</td>
<td>80 mg</td>
<td>Once daily on days 2, 3</td>
<td>182.14</td>
<td>364.28</td>
</tr>
<tr>
<td>Fosaprepitant IV</td>
<td>150 mg</td>
<td>Prechemotherapy, one dose</td>
<td>299.87</td>
<td>299.87</td>
</tr>
<tr>
<td>Rolapitant</td>
<td>180 mg</td>
<td>Prechemotherapy, one dose</td>
<td>610.50</td>
<td>610.50</td>
</tr>
<tr>
<td><strong>Combination products</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Netupitant/palonsetron)</td>
<td>300 mg /0.5 mg</td>
<td>Prechemotherapy, one dose</td>
<td>632.35</td>
<td>632.35</td>
</tr>
<tr>
<td><strong>Antipsychotics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug Type</td>
<td>Strength/Route</td>
<td>Dose/Instruction</td>
<td>Days</td>
<td>Cost 1</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------</td>
<td>----------------------------------</td>
<td>------</td>
<td>--------</td>
</tr>
<tr>
<td>Olanzapine (generic)</td>
<td>5 mg</td>
<td>Once daily on days 1-3</td>
<td></td>
<td>6.50</td>
</tr>
<tr>
<td>Olanzapine (generic)</td>
<td>10 mg</td>
<td>Once daily on days 1-3</td>
<td></td>
<td>6.50</td>
</tr>
<tr>
<td>Olanzapine (brand)</td>
<td>5 mg</td>
<td>Once daily on days 1-3</td>
<td></td>
<td>15.07</td>
</tr>
<tr>
<td>Olanzapine (brand)</td>
<td>10 mg</td>
<td>Once daily on days 1-3</td>
<td></td>
<td>22.21</td>
</tr>
</tbody>
</table>

**Dopaminergic antagonists**

<table>
<thead>
<tr>
<th>Drug Type</th>
<th>Strength/Route</th>
<th>Dose/Instruction</th>
<th>Days</th>
<th>Cost 1</th>
<th>Cost 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide IV</td>
<td>1 to 2 mg/kg</td>
<td>Prechemotherapy, one dose</td>
<td></td>
<td>99.50</td>
<td>99.50</td>
</tr>
<tr>
<td></td>
<td>0.5 mg/kg</td>
<td>Every 6 hours, days 2-4</td>
<td></td>
<td>6.50</td>
<td>6.50</td>
</tr>
<tr>
<td>Metoclopramide oral (generic)</td>
<td>0.5 mg/kg</td>
<td>Prechemotherapy, every 6-8 hours, maximum 40 mg</td>
<td></td>
<td>65.00</td>
<td>192.99</td>
</tr>
<tr>
<td>Metoclopramide oral (brand)</td>
<td>0.5 mg/kg</td>
<td>Prechemotherapy, every 6-8 hours, maximum 40 mg</td>
<td></td>
<td>11.93</td>
<td>11.93</td>
</tr>
<tr>
<td>Prochlorperazine IV</td>
<td>5-10 mg</td>
<td>Every 6 to 8 hours as needed</td>
<td></td>
<td>6.50</td>
<td>6.50</td>
</tr>
<tr>
<td>Prochlorperazine oral</td>
<td>10 mg</td>
<td>Twice daily, days 1-3</td>
<td></td>
<td>75.38</td>
<td>249.63</td>
</tr>
<tr>
<td></td>
<td>5 mg/m²</td>
<td>Every 2-4 hours as needed</td>
<td></td>
<td>184.70</td>
<td>223.94‡</td>
</tr>
<tr>
<td>Dronabinol oral (generic)</td>
<td>5 mg/m²</td>
<td>Every 2-4 hours as needed</td>
<td></td>
<td>314.60</td>
<td>941.80‡</td>
</tr>
</tbody>
</table>

*C* Schedules were those recommended as antiemetic drug doses as of October 4, 2016. Prices per dose were for a single infusion or per pill for orally administered medications. Prices for infused drugs reimbursed through Medicare Part B only were identified from the 2016 Medicare Part B Drug Average Sales Price Data (https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McPartBDrugAvgSalesPrice/index.html). Prices for orally administered drugs reimbursed through Medicare Part D were identified in the PlanFinder for a beneficiary living within ZIP code 10065 (www.medicare.gov). To remain as consistent as possible with prior methodology, we selected a Humana PDP plan with the lowest cost for beneficiaries to identify the full cost of each drug (Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. The New England Journal of Medicine. 2009;360(6):626-33. AND https://www.mskcc.org/sites/default/files/node/25097/documents/methods-for-drug-price-calculations-12.9.15.pdf).

Drug costs may vary by plan and by pharmacy where a prescription is filled (eg, preferred or nonpreferred pharmacies). In some cases, antiemetic coverage for orally administered drugs may be covered by either Part B or Part D. We have selected the Medicare Part D price in these cases. Note: drug prices are dynamic and the prices listed in the table may not reflect current prices. In some cases, the recorded out-of-pocket price per dose is equivalent to the price per cycle. This may represent a minimum price per fill set by the health plan.

† Price information not yet available through Medicare.

‡ Assume 3 days use, 12 pills per day.